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ABSTRACT OF THE DISSERTATION 
Siderophore-Dependent Transport Paradigms for Iron Across the Bacterial Cell Envelope in the 
Human Pathogen Staphylococcus aureus  
by 
Nathaniel P. Endicott 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2019 
Professor Timothy A. Wencewicz, Chair 
This work is focused on iron trafficking through ABC transporters in Staphylococcus 
aureus and combatting the growing antimicrobial resistance crisis by exploiting virulence factors 
as therapeutic targets. Specifically, the goal was to understand the role of a siderophore-binding 
lipoprotein FhuD2 in S. aureus iron trafficking. While S. aureus endogenously produces three 
metallophores for metal sequestration from the host, FhuD2 is thought to scavenge metals from 
hydroxamate-based xenosiderophores encountered in the host environment. FhuD2 is a critical 
virulence factor and vaccine candidate (Novartis) for MRSA. Since xenosiderophore scavenging 
systems are often dispensable, it was hypothesized that FhuD2 must be playing another role to 
enhance pathogen virulence. Through careful investigations using a fluorescent siderophore probe, 
this work has revealed a new role for FhuD2 in the S. aureus iron trafficking pathway. FhuD2 does 
tightly bind hydroxamate xenosiderophores, but it does not immediately use the siderophore as a 
transport substrate. Instead, the siderophore serves as a cofactor for a newly proposed enzymatic 
function of FhuD2 in iron trafficking from human holo-transferrin. Using a “turn-off” fluorescent 
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siderophore probe it was shown that the FhuD2 apo-siderophore complex is capable of catalyzing 
iron extraction from transferrin. The interaction of FhuD2 with transferrin better explains its role 
as a virulence factor and establishes a new paradigm for iron trafficking in bacteria with broad 
relevance. This same phenomenon was confirmed another human pathogen, Bacillus subtilis. 
Structure-activity relationship analysis of siderophores governing cell entry revealed a charge-




















This chapter was written by Nathaniel Endicott (NPE) with feedback provided by Dr. Tim 
Wencewicz (TAW). 
1.2 The Antimicrobial Resistance Crisis 
Antimicrobial resistance is one of the most pressing problems facing modern society. It is 
projected to eclipse cancer in yearly annual death globally by 2050 if not addressed. The history 
of antibiotic development originated with the discovery of penicillin by Alexander Fleming in 
1928.1 Penicillin was one of the most successful antibiotics in history and was heavily used in 
World War II.2 Resistance to penicillin became an increasing problem throughout the 1950s, but 
new antibiotics were developed which temporarily solved the penicillin resistance problem in what 
is coined the Golden Age of antibiotic discovery. However, resistance began growing in multiple 
areas until resistance was seen in nearly every class of antibiotics, while simultaneously fewer new 
classes of drugs were discovered.3,4  
There are multiple underlying causes of the spread of antibiotic resistance. The overuse of 
antibiotics is a major contributing factor, due to horizontal gene transfer allowing resistance to 
rapidly spread between different species of bacteria. Resistance spontaneously occurs through 
mutation, and the use of antibiotics directly fuels the natural selection of drug-resistance strains 
and leaves enriched pools of resistant pathogens to survive at an infection site. 5 Overuse of 
antibiotics often results from inadequate stewardship including prescription practices. About 30% 
to 50% of the time, the choice of antibiotic, duration of administration or treatment indication are 
inappropriate for a given indication.6 Unnecessary durations of treatment results in extended 
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evolutionary pressure for drug resistant strains to survive, and subtherapeutic concentrations 
promote this process further. Use of antibiotics in agriculture is another factor, as they are widely 
used for livestock growth supplements.7 It is financially profitable for the agricultural industry to 
use copious amounts of antibiotics because of the positive effect in animal health leading to higher 
yields and product quality. This practice makes agricultural settings reservoirs of antibiotic 
resistant bacteria, including some human pathogenic strains. Unfortunately, when the animals are 
eaten the antibiotics and antibiotic resistance genes harbored within them are transferred to humans 
after consumption, resulting in enhanced exposure of human commensals to antibiotics and 
associated resistance that can be accommodated long-term by the gut microbiome of an 
individual.8 Agricultural antibiotic use can disrupt the balance of native microbiomes and excreted 
antibiotics in urine or stool of ingesting animals spreads throughout soil and is widely distributed 
by groundwater, fertilizer and surface runoff.7 
Adding to the resistance problem is the glaring lack of new antibiotic development by the 
pharmaceutical industry. Regulatory and economic issues are the main barriers preventing 
development of new antibiotics.7 From an economic standpoint, antibiotics pose a problem due to 
them often completely curing an infection while only being needed for short periods of time. 
Chronic illnesses requiring continual treatment are much more desirable research targets in this 
regard. The current estimated market value of net present value of new developed antibiotics is 
$50 million, only 5% of the estimated value of a drug used to treat a neuromuscular disease.7 
Antibiotics cost consumers relatively less than other types of treatments, one notable example 
being the high cost of cancer treatment. Another way in which antibiotic development is not 
profitable lies in their common use as treatments of last resort, due to infectious-disease specialist 
recommendations of limiting antibiotic use.9 Resistance emerging from the use of new antibiotics 
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is inevitable, but the timeline dissemination is often unpredictable, making newly discovered 
antibiotics at risk for quickly becoming obsolete. Additionally, because many antibiotics are now 
off-patent, they are supplied by generic drug manufacturers, resulting in both effective and cheap 
drugs for common ailments. This results in a public expectation that new antibiotics might be 
priced similarly, posing the problem of potential backlash for companies in antibiotic 
development.1 Few antibacterial drugs have reached phase 2 or 3 in development as of 2013, 
especially those that could deal with some of the ESKAPE pathogens, such as Pseudomonas 
aeruginosa, Acinetobacter baumanii, and Enterobacteriaceae.10 
Regulatory barriers represent an obstacle in the development of new antibiotics due to 
issues such as changes in licensing and other regulation rules, bureaucracy, and ranging amounts 
of clinical trial requirements for different countries. The U.S. Food and Drug Administration has 
raised the standard for clinical trial quality over the past several years, resulting in high cost and 
high populations required for new drug trials. Many smaller companies cannot afford the cost of 
phase 3 trials.11 There is hope on the horizon for more efficient regulatory practices, however, as 
the Infectious Diseases Society of America has proposed a novel regulatory pathway based on 
smaller population sizes, resulting in a much faster and cheaper pathway to navigate clinical trials. 
The downside of this approach is new antibiotics would be designed to specifically treat only high-
risk patients who could afford to take on the potential side effects of the specific drug. Limiting 
the exposure of new drugs to smaller populations does have the advantage of minimizing the 
spread of resistance, but lacks the profitability needed to drive discovery in the private sector and 




1.3 Multidrug Resistance 
The antimicrobial resistance landscape is dominated by multidrug resistant strains of 
bacteria, notable examples being vancomycin-resistant Enterococci, carbapenem-resistant 
Enterobacteriaceae, multidrug resistant Pseudomonas aeruginosa, and methicillin-resistant 
Staphylococcus aureus (MRSA). Enterococci present a problem due to their role in a variety of 
illnesses, affecting areas such as the urinary tract and the bloodstream. Around 30% of 
enterococcal infections are vancomycin-resistant, which leads to around 1,300 deaths per year in 
the United States. Although some antibiotic options, such as linezolid, are available to treat 
vancomycin-resistant strains, the total number of vancomycin-resistant infections has reached over 
20,000 per year necessitating the discovery of new drugs in this area.3 Carbapenem-resistant 
Enterobacteriaceae are considered resistant against nearly all available antibiotics. Almost 600 
deaths per year result from infections caused by carbapenem-resistant Enterobacteriaceae, fueled 
by the presence of an enzyme called NDM-1 that confers this high resistance to beta-lactam 
antibiotics.2,3 Multidrug-resistant Pseudomonas aeruginosa occur primarily in the urinary tract and 
surgical sites and pose a major problem for cystic fibrosis patients in the form of pulmonary 
infections. 6,000 cases per year of P. aeruginosa are multidrug-resistant, and around 400 deaths 
per year are caused by these resistant strains, some of which have shown resistance to almost all 
known antibiotics.3 
Methicillin-resistant Staphylococcus aureus (MRSA) represents one of the most serious 
antibiotic-resistant threats known, resulting in over 11,000 deaths per year in the U.S. alone.12 First 
discovered almost 50 years ago, MRSA is highly resistant to beta-lactam antibiotics and several 
other drug classes.2,4 Although many drugs retain activity against MRSA, such as linezolid, 
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tigecycline, and ceftobiprole, MRSA has shown insidious ability to spread and thrive in various 
different types of epidemiological settings, ranging from animals, hospitals and communities.13 
Thus, a focus on healthcare associated infections is not enough when studying and managing 
MRSA. Many of the endogenous resistance mechanisms in MRSA are transferable on plasmids 
including resistance to glycopeptides and linezolid, drugs of last resort.13 There has been some 
progress addressing the issue of healthcare associated MRSA, primarily through improvement of 
hygiene practices in hospital settings, but community-associated infection rates caused by MRSA 
have been on the rise, likely due to the difficulties of controlling hygiene in public settings 
compared to hospitals.3,13 
An important technique in researching solutions to the antimicrobial resistance problem is 
to focus on bacterial virulence as potentially underexplored targets to develop bacteriostatic 
antibiotics. While bactericidal antibiotics outright kill an infection of interest, bacteriostatic 
antibiotics only stagnate growth. Although a priori bacteriostatic treatments seem like an inferior 
approach, they have several advantages. Firstly, they create less evolutionary pressure on bacteria 
to develop resistance. Bactericidal treatments leave only resistant strains remaining, meaning once 
the resistant strains multiply, they represent a much a higher percentage of the given population 
(Figure 1.1). Secondly, bacteriostatic treatments place a greater burden on the body’s own defense 
systems to rid the body of the infection, having a similar effect as that of a vaccine, leaving the 





1.4 Virulence Factors of S. aureus 
S. aureus possesses several key virulence factors allowing it to invade and circumvent 
protections by the innate immune system.16 Exoproteins are present in almost all types of S. aureus 
strains, ranging from exotoxins to multiple kinds of enzymes, such as proteases, lipases, and 
collagenase. Using these proteins, local host tissue can often be converted into nutrients allowing 
for bacterial growth.17 Some of the exotoxins produced by S. aureus are cytolytic, forming β-barrel 
plasma membrane pores which results in lysis of the targeted cell.18 Some examples of these 
cytolytic toxins produced by S. aureus are the hemolysins and leukocidins.19 α-hemolysin is 
especially cytolytic toward monocytes and human platelets. This toxin is a pore former, which can 
often result in changes of iron gradients, activation of signaling pathways for stress, and membrane 
integrity loss.20 Panton-Valentine leukocidin targets leukocytes, and γ-hemolysin targets 
erythrocytes, and is a known necrotizing disease virulence factor. 18 Two aspects of the toxin are 
each important in pore formation, LukS-PV and LukF-PV, which work together to form an 
octameric β-barrel complex which lies perpendicular to the cell membrane plane. 19 Another type 
of exotoxins produced by S. aureus are the staphylococcal enterotoxins, the exfoliative toxins, and 
the toxic shock syndrome toxin-1, which is considered a pyrogenic toxin superantigen.22 
Superantigenicity refers to the toxin’s ability to spur propagation of T-lymphocytes, which cause 
food poisoning and shock syndrome (Figure 1.3).23 Exfoliative toxins have also been implicated 
in T lymphocyte proliferation.24 S. aureus produces other proteins which affect the immune 
system, such as the staphylococcal complement inhibitor, which blocks C3b formation on the 
bacterium surface, interfering with phagocytosis of S. aureus cells by human neutrophils.25 The 
chemotaxis inhibitory protein extracellular fibrinogen binding protein both function to block 
neutrophil receptors from chemoattractants.26 A formyl peptide receptor-like-1 inhibitory protein 
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blocks neutrophil migration to tissue from blood vessels.27 Staphylokinase binds to α-defensins to 
eliminate their bactericidal activity.28 
Adhesion proteins play an important role in the ability of S. aureus to initiate the 
colonization process on host cells. The microbial surface component recognizing adhesive matrix 
molecules are comprised of covalently anchored proteins to cell peptidoglycans which attach to 
the extracellular matrix.29 Perhaps the most notable protein in this family is SpA, which has been 
shown to be vital in inducing pneumonia.30 Mice models have confirmed that the lack of SpA 
reduces rates of pneumonia and mortality. SpA is 42-kDa in size and covalently anchors to the 
bacterial cell wall, and it binds a large glycoprotein called the von Willebrand factor that 
participates in healing endothelial damage through platelet adhesion.31 The five repeated domains 
of SpA all bind with high affinity to immunoglobulin G in the Fc region.32 The binding to the Fc 
region of immunoglobulin G triggers a conformational shift that causes the bacteria not to be 
recognized by polymorphonuclear leukocytes (Figure 1.4).33 
Virulence factors in S. aureus are highly regulated by a variety of environmental cues. 
Temperature, osmolarity, pH, oxygen tension and nutrient availability all influence virulence 
factor expression.34 Production of virulence factors is controlled by multiple global regulatory loci, 
such as the staphylococcal accessory regulators and ferric uptake regulators (Fur).34,35 These kinds 
of regulators are part of an intricate network that modulates expression of virulence genes. A 
specific target virulence gene has the ability to be influenced by many different regulators that can 
“cross talk” to make sure that the gene is only expressed in favorable conditions. For example, agr 
has been shown to negatively regulate spa expression, which encodes for SpA production.36 On 
the other hand, SarS binding to the spa promoter activates SpA expression.37 Intriguingly, agr also 
downregulates sarS expression.35 It therefore appears that the mechanism by which agr 
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downregulates expression of spa is through suppression of sarS.37 Virulence gene regulators can 
therefore affect target gene expression by directly binding to promoters or they can play an indirect 
role via other regulators. 
1.5 The Importance of Iron in Bacterial Virulence 
Regulation of iron uptake through the ferric uptake regulators is imperative for any 
invading pathogen such as S. aureus to survive. Iron acquisition plays a crucial role in bacterial 
virulence. Iron is vital for the survival of nearly all organisms, as processes such as electron 
transport, nitrogen fixation, DNA replication, photosynthesis, amino acid biosynthesis and 
tricarboxylic acid cycle all require iron.38 Other processes such as virulence factor expression, 
symbiosis and host colonization all are highly relevant to the iron problem.39 One reason why iron 
uptake is highly regulated is not just because of its beneficial nature, as excess iron can also be 
detrimental, leading to hydroxyl radical, superoxide and hydrogen peroxide generation.40,41 
Reactive oxygen species result in DNA damage, membrane dysfunction, protein damage, and lipid 
peroxidation.42,43  
Iron exists either as ferric Fe(III) in its oxidized form or ferrous Fe(II) in its reduced form. 
Bacteria require approximately 10-6 M iron to survive, but ferric iron is highly restricted down to 
10-24 M levels in biological settings, sequestered into iron-sulfur proteins, heme, and iron storage 
proteins such as transferrin (Figure 1.5).44 For many bacteria such as S. aureus, ferric uptake 
regulators act as a global sensor of iron in the intracellular environment by coordinating 
transcription of genes responsive to iron with the available iron.45 Iron acquisition in S. aureus is 
illustrated by the reduced virulence in animal models when iron acquisition is disrupted.46 
Staphylococcal stains which are defective in heme uptake, however, are not significantly affected 
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in virulence for murine pneumonia models, indicating heme iron alone is not necessary for S. 
aureus proliferation in murine lungs.47 Fur-mediated iron availability sensing is conserved across 
many different strains of Gram-negative and Gram-positive bacteria such as S. aureus.48 In iron 
rich environments, Fur generally functions as a repressor with the ability to bind DNA, inhibiting 
expression of select genes important for iron uptake. In iron-limited environments, such as an 
infection site, this Fur repression is attenuated, and the same genes are then expressed.49,50 Fur 
regulates not only genes encoding systems for iron acquisition, but also influences many 
cytoplasmic proteins, plays a role in the expression of stress proteins with antioxidative properties, 
and is involved in the formation of biofilms.51,52,53 
1.6 Siderophore Utilization for Iron Acquisition 
The relevance of iron acquisition necessitates multiple avenues of iron transport for 
bacteria. The production of siderophores represents one of the most relevant virulence factors in 
this area. Siderophores are small molecules with high iron affinity, produced additionally by plants 
and fungi but not mammals.54,55,56 Siderophores commonly bind iron through bidentate chelating 
motifs such as catecholates, phenolate oxazolines, α-hydroxycarboxylic acids, and hydroxamates, 
where the hard oxygen donors match well to hard ferric iron.57 Combinations of bidentate metal-
chelating groups in a siderophore scaffold facilitates the hexadentate coordination to the metal 
center necessary for achieving the desired octahedral geometry. Often the ligands are preorganized 
around the metal on macrocyclic siderophore scaffolds.57 Many bacteria can produce and utilize 
multiple different siderophores. In E. coli, for example, can utilize ferric complexes of 
rhodotorulate, coprogen, ferrichrome, citrate, enterobactin, and linearized enterobactin.58 
Interestingly, rhodotorulate, coprogen and ferrichrome are not produced by E. coli itself. This use 
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of xenosiderophores is a common strategy by bacteria in order to lessen metabolic burden.59 Other 
notable examples of xenosiderophores are enterobactin uptake in Pseudomonas aeruginosa and 
ferrioxamine in Yersinia enterocolitica and S. aureus.60,61 Biosynthesized within the cell, 
siderophores are sent into the extracellular environment via efflux pumps, where they return back 
through the cell membrane through the use of membrane-anchored ABC transporters (Figure 
1.6).57 
The logic behind bacteria being able to utilize multiple different siderophores can be 
explained in that different siderophores can have specific advantages to unique environmental 
conditions.62 In Salmonella enterica, for example, enterobactin is produced to satisfy nutritional 
requirements, but the human body has evolved a defense system against this route for iron 
acquisition. The defense protein lipocalin-2 binds and directly sequesters ferric enterobactin.57 
Salmonella counteracts this by producing salmochelins, glucosylated enterobactin derivatives that 
are unable to be captured by lipocalin-2.63,64 Salmochelin production has also been observed in 
various strains of E. coli.64 In the case of P. aeruginosa, the two siderophores it produces, 
pyoverdine and pyochelin have orders of magnitude difference in their ability to coordinate 
Fe(III).65,66 Mathematical simulations illustrate the ability of P. aeruginosa to switch between 
producing each of these siderophores in response to varying iron conditions gives it a fitness 
advantage over strains that do not have this functionality.67 
1.7 Siderophore System in S. aureus 
The iron uptake system in S. aureus specifically is like many other bacteria in terms of 
regulation and strategies to acquire iron. The mechanism of Fur binding to the fur box on DNA in 
iron-rich conditions followed by the release of Fur from DNA in iron depleted conditions holds 
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true for S. aureus, resulting in transcriptional repression of the regulon for Fur when iron is 
bountiful and de-repression when iron is scarce.68,69 S. aureus strains deficient in fur exhibit a 
profile of gene expression mirroring an iron starved organism. Mice infected with S. aureus have 
been imaged for gene transcription revealing that Fur-regulated genes become expressed in kidney 
and heart abscesses, indicating the bacteria has iron starved in these locations.70,71 Cytoplasmic 
protein profiles for wild type S. aureus have been compared to an isogenic fur mutant and it was 
found that there are twenty different staphylococcal proteins that are at a higher abundance without 
the presence of Fur, indicating they are negatively regulated by Fur.72 A further analysis indicated 
increased levels in fermentative and glycolytic enzymes, pointing toward the ability of S. aureus 
to modulate its metabolism to adapt to iron-starved host environments.69 For iron-limited 
conditions, an increase in fermentative metabolism causes an increase in lactate production, which 
lowers the environmental pH to therefore negatively affect the affinity for transferrin to bind iron. 
In S. aureus, Fur regulates multiple virulence factors specifically, such as the expression of its 
immunomodulatory and cytolytic toxins and siderophores.69 
The native S. aureus siderophore system constitutes of two different siderophores, 
staphyloferrin A and staphyloferrin B (Figure 1.7). The genes important for the biosynthesis of 
staphyloferrin A and B are directly regulated by Fur and are highly expressed in iron-deficient 
conditions.72 Synthesized forms of each of these siderophores have shown the ability to restore the 
defects of staphylococcal mutants unable to produce each respective siderophore.69 Although a 
third siderophore in S. aureus has been implicated as existing, aureochelin, the molecule has not 
been fully characterized.74 Mutants unable to synthesize staphyloferrin A and B in isolated 
supernatants cannot support wild type growth of S. aureus with no iron present, indicating 
aureochelin, if present, does not play a significant role in iron acquisition on its own.75 
15 
 
Additionally, iron acquisition from sources such as transferrin has been implicated to be related to 
siderophores, though S. aureus does not produce a direct transferrin receptor.58  
Staphyloferrin A on its own has shown relevance in iron acquisition. Mutants lacking the 
ability to produce staphyloferrin B have shown capability to sustain some growth in serum.75 The 
sfnABCD operon encodes for staphyloferrin A production, which was found through bioinformatic 
screening and confirmed by biochemical and genetic approaches (Figure 1.8).77 Although 
sfnABCD inactivation fails to attenuate growth of S. aureus growth in serum, its inactivation in a 
mutant without the capability to produce staphyloferrin B results in greatly impaired S. aureus 
growth.75 ABC transporters often are present close to the genes required for siderophore 
production. Genes encoding for HtsABC, the transporter involved in uptake of staphyloferrin A, 
are located adjacent to the sfn operon. HtsABC has also been linked to heme binding, indicating 
that its role might be promiscuous and relevant in multiple types of iron uptake. 75 The crystal 
structure of HtsA was the first siderophore receptor of its kind to be characterized from a Gram-
positive bacterium, and this structure directly supports the involvement of HtsA in siderophore 
utilization, which occurs through a conformational change of HtsA upon staphyloferrin A binding 
which entraps the siderophore substrate.78 One noteworthy aspect of the crystal structure is the 
likelihood that HtsA does not directly bind heme, implicating the possibility of another lipoprotein 
acting as a conduit for heme transport.69 
Staphyloferrin B synthesis is encoded by the sbnABCDEFGHI operon (Figure 1.8).79 Its 
import through the membrane occurs by sirABC, with SirBC as the membrane permease 
component of staphyloferrin B import to the cytoplasm and SirA as the lipoprotein receptor 
involved in binding staphyloferrin B from the extracellular environment.80 The conformational 
change in SirA encloses staphyloferrin B in the binding pocket, analogous to HtsA.81 Both HtsA 
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and SirA bind their respective substrates with low nanomolar association constants, illustrating the 
tailored evolution of S. aureus to acquire iron in an infection setting.69 The presence of both 
staphyloferrin A and B in S. aureus indicates each siderophore possibly performing unique roles, 
such as scavenging iron from different host proteins or performing more efficiently in different 
infection settings. 
Many transitions metals other than iron, such as copper, nickel, zinc and cobalt are crucial 
to biological processes, having relevance in areas such as enzymatic reactions, signaling agents 
and protein stability. S. aureus possesses several transition-metal transport systems, such as NixA, 
Nik, Adc, and Cnt.82 The Nik system is an ATP-binding cassette (ABC) transporter important for 
nickel acquisition, composed of the solute-binding protein (SBP) portion NikA and NikBCDE to 
form the rest of the transport channel. The Nik system takes advantage of L-histidine and other 
small-molecule chelators to determine urease activity, transport nickel, and colonize the urinary 
tract in mice.83-85 The NixA  system has similar functions, such as impacting urease activity and 
playing a role in kidney colonization.83 Adc, composed of the metal-binding component AdcA and 
the ABC transporter AdcBC, is involved in zinc acquisition.86 Cnt, while originally shown as a 
nickel and cobalt acquisition system, has been shown to transport additional metals, such as zinc, 
iron, manganese, and copper depending on environmental conditions.87,88 The substrate for the Cnt 
system is the general metallophore staphylopine, representing an additional native metal binder in 





1.8 ABC Transporters 
The ABC transports involved in the uptake of staphyloferrin A, B, and staphylopine are 
part of the family ATP-powered pumps. The pumps use energy from ATP hydrolysis to move the 
specific substrate across membranes or into cellular vesicles against the electrochemical gradient 
of the environment.89 ABC pumps constitute a large, diverse superfamily, and most of the ABC 
genes encode membrane-anchored proteins participating directly in molecular membrane 
transport.90 Depending on the directionality of cytoplasmic transport, these transporters can be 
characterized as importers or exporters.91 The ABC proteins are constituted of the nucleotide 
binding domain (NBD), which contains several conserved motifs such as the Walker A and B 
sequences, the ABC signature motif, and Q loop and the H loop. Also present are the 
transmembrane domains (TMDs), which are composed of multiple hydrophobic α-helicies. 
Overall the core unit of the ABC transporter contains two NBDs along with two TMDs. The two 
NBDs bind together and function to hydrolyze ATP, providing the transportation driving force, 
and the TMDs are important in substrate recognition as well as translocation through the lipid 
membrane.90 ABC transporters often contain a membrane-bound substrate-binding protein (SBP) 
portion relevant for delivering the substrate to the importer complex (Figure 1.9). ABCC 
transporters are a subfamily of the ABC transporters relevant in S. aureus. One of the activities 
relevant to the ABCC transporters includes toxin excretion, involving several fungal and bacterial 
toxins.93 Another important aspect is xenosiderophore utilization as seen in the Fhu system (Figure 
1.9).94 
ABC transporters are associated with an ATPase, but sirABC and htsABC operons both do 
not encode a putative ATPase.95 The fur operon in S. aureus, fhuCBG, however, does encode a 
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putative ATPase, fhuC, which is necessary for the transport of staphyloferrin A and B.75 A fhuCBG 
mutant showed inhibited growth in iron-deficient conditions that is not recovered by the addition 
of staphylferrin A or B on their own, but the presence of fhuC in addition to staphyloferrin A or B 
does recover growth, indicating FhuC is highly relevant in S. aureus iron acquisition.75 
Hydroxamate siderophores not directly produced by S. aureus can be utilized by S. aureus to help 
establish residency in the microbiome (Figure 1.7).69 fhuCBG is directly related to the uptake of 
xenosiderophores in S. aureus, along with the lipoprotein receptors FhuD1 and FhuD2, located at 
distinct loci in the S. aureus genome (Figure 1.8).96 FhuD1 and FhuD2 only undergo moderate 
conformational changes upon binding their siderophore substrate, unlike SirA and HtsA.97,98 Less 
conformational change naturally leads to less affinity for any one specific siderophore, but it 
creates promiscuity for multiple kinds of siderophores, allowing S. aureus to run a separate 
xenosiderophore stealing platform in addition to its uptake of staphyloferrin A and B (Figure 
1.10).  
1.9 Clinical Relevance of Xenosiderophore Utilization 
Utilization of xenosiderophores by S. aureus has consequences on clinical use of the 
siderophore desferrioxamine B (DFO) as a first line therapeutic in treating iron overload disease, 
The large dose of DFO provides an easy source of iron for a local S. aureus infection to flourish. 
S. aureus is the most common infection for thalassemic patients treated with DFO in order to 
reduce blood iron levels after blood transfusions which are a necessary form of treatment.99 Even 
as other types of iron overload treatments have grown in popularity, combination therapy with 
DFO and other iron chelators has shown promise in circumstances in which monotherapy is not 
adequate, assuring the clinical importance of DFO in the near future.100 In addition to its use in 
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treating iron overload, DFO has shown promise as a delivery vector for antibiotics and otherh types 
of molecular cargo with potential applications for infection imaging, cancer, Parkinson’s, 
Alzheimer’s, and COPD.101-106  
Elucidation of the membrane transport paradigms for siderophores such as DFO at the ABC 
transporter level is critical for intelligent design of future siderophore-based therapeutics. 
Reducing infection risk and increasing efficacy of siderophore therapeutics are directly linked to 
understanding cell entry. In this dissertation, the different mechanistic possibilities of a holo-
siderophore approaching Gram-positive cell membrane will be discussed in the context of the DFO 
and FhuD2 system in S. aureus. Molecular mechanisms for siderophore recognition, transport, and 
utilization as an iron source were explored through a fluorescence quenching assay using a 
siderophore probe molecule to monitor iron exchange processes, resin-immobilized FhuD2 to 
evaluate the reversibility of siderophore binding, and a rationally designed panel of DFO analogs 
to probe structural elements that influence cell entry in S. aureus.  
1.10 Mechanism of Iron Transport 
The answer to the question of determining cell entry revolves around understanding the 
possible mechanisms by which cell entry can occur.  Once a siderophore has acquired iron in the 
extracellular environment and returns to the cell membrane, it has three options. In the first option, 
it can directly bind to the SBP and then pass through the ABC transporter in order to gain access 
to the interior of the cell. This is the currently accepted model for vitamin B12 transport in bacteria 
and is conceptually the simplest option for cell entry (Figure 1.11).107 One noteworthy aspect of 
bacterial ABC transporters, however, is the presence of apo-siderophores commonly bound to the 
surface of the SBP. This is the most likely state for an SBP dictated by the concentration gradient 
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of apo-siderophores being excreted from the interior of the cell. The second option for membrane 
transport involves an apo-siderophore bound to the SBP as a holo-siderophore approaches the cell. 
In this mechanism, the holo-siderophore competitively displaces the apo-siderophore at the SBP 
active site.108 The holo-siderophore then gains cell entry. The third mechanism involves the same 
situation, an apo-siderophore bound to the SBP and an approaching holo-siderophore. Instead of 
displacement at the SBP, though, the incoming holo-siderophore non-reductively shuttles its iron 
to the SBP-bound apo-siderophore. The new holo-siderophore then enters the cell.109 Several 
unanswered big picture questions remain surrounding these membrane transport paradigms and 
were recently defined by the work of Professor Ken Raymond.108 Notably, the conditions favoring 
the shuttle or displacement mechanism are unknown. The biological reason behind having multiple 
different mechanistic pathways was also unclear. The specific mechanistic detail behind the shuttle 
mechanism was additionally left in the dark. The non-reductive shuttle of iron would logically be 
a kinetically slow process, pointing to the possible role of the SBP as a catalyst in this exchange. 
There is precedent for the evolution of catalytic effects originating from initially non-catalytic 
proteins, and FhuD2 showing potential as a vaccine candidate points to its significance in S. aureus 
virulence (Figure 1.14).110 In chapter 2, the structure-activity relationship rules for cell entry in a 
panel of DFO analogs was analyzed in detail, and negative charge ultimately dictated the ability 
for S. aureus to acquire holo-siderophores from the environment. In chapter 3, the mechanistic 
details of the shuttle and displacement mechanism were studied and a new paradigm for 
siderophore-mediated iron acquisition is proposed involving siderophores as cofactors in the 
enzymatic transfer of iron from human defense proteins such as transferrin. The logic used in the 
experimental design and execution proves insight on the siderophore system and iron acquisition 





                        
 
Figure 1.1. Overview of the problem of bactericidal treatment. Bactericidal antibiotic treatment 
leaving only drug-resistant strains behind results in high evolutionary pressure for only the drug-
resistant strains to survive. (A) An infection site is a complex equilibrium of invading bacteria and 
body defense cells such as phagocytes. (B) Administration of a bactericidal antibiotic kills of 
susceptible bacteria leaving behind a small population of resistant cells that can evade host defense 
cells (C) Resistant cells can dominate the population and the body’s immune system has not 
responded to the pathogen. (D) Administration of the same antibiotic becomes less effective once 
the population of drug-resistant strains becomes much higher. (E) Left without an effective answer, 









Figure 1.2. Favorable outcomes from bacteriostatic treatment. If an antibiotic only exhibits 
bacteriostatic effects, it can allow the body’s own immune system to deal with the infection by 
halting pathogen growth and allowing for an innate and adaptive immune response. This applies 
less evolutionary pressure on drug-resistant strains to survive as well as leaving the body’s own 
immune system better adapted to handle future infections, like a vaccine. (A) Administration of a 
bacteriostatic antibiotic has the benefit of often being useful for a specific bacterial target, leaving 
the host defense cells free to recognize the pathogen. (B) If the bacterial infection has been 
stagnated after bacteriostatic treatment, the innate immune system can clear the infection. (C) The 
immune system is left better able to handle future infections after being adapted to deal with the 
most recent one. 
 
 






Figure 1.3. Common exotoxins of S. aureus. Pictured above is α-hemolysin, a pore former that is 
cytolytic. Pore formation has several potentially negative effects on cells, notably loss of 
membrane integrity. Pictured below is Panton-Valentine leukocidin, LukS-PV on the left and 
LukF-PV in the middle. Each work in concert to form an octameric β-barrel complex lying on the 
cell membrane. Pictured on the lower right is toxic shock syndrome toxin-1, which can encourage 









Figure 1.4. The adhesion protein SpA of S. aureus. SpA (purple) bound to the Fc region of 
immunoglobulin G. The conformational shift triggered by this binding event safeguards S. aureus 
from recognition by polymorphonuclear leukocytes. PDB entry number is provided. Image was 























Figure 1.5. Common sources of iron in the body. Transferrrin (left) is a human defense protein 
specializing in iron sequestration. Heme (right, pictured in its form heme B) is most common 









Figure 1.6. Overview of siderophore-mediated iron acquisition in Gram-positive bacteria. Shown 
is an example of hexadentate chelation of Fe(III) in the siderophore staphyloferrin A, a binding 
mode shared by ferrioxamine B. On the right the general pathway of siderophores is illustrated. 
Siderophores are biosynthesized intracellular before being sent into the extracellular environment 
via efflux pumps. Iron-bound siderophores then return to the interior of the cell by membrane-









Figure 1.7. Native siderophores and metallophores of S. aureus with their corresponding 
membrane transporter systems. S. aureus can notably utilize hydroxamate siderophores such as 












Figure 1.8. Gene loci important for S. aureus iron acquisition. For staphyloferrin A biosynthesis, 
the genes required are encoded by the sfa operon. The sbn operon genes encode staphyloferrin B 
biosynthesis. Purple ovals indicate promotor regions that contain a consensus fur box. Genes are 






Figure 1.9. Homology model of the Fhu uptake system to BtuCDF. BtuCDF is the bacterial 
importer of vitamin B12. The molecular dynamics of the NBDs (black, bottom) and the TMDs 
(light gray, middle) along with the SBP region (dark gray, top) are thought to be highly conserved 





Figure 1.10. FhuD2 binding pocket. The binding pocket of FhuD2 is charge-neutral, allowing for 
the promiscuous binding of many different siderophore substrates. There only appears to be a 
single distinct location for siderophore binding. Minimal conformational change occurs when the 











Figure 1.11. Canonical mechanism for cell entry. Seen in the case of the bacterial import of 
vitamin B12, the canonical pathway only involves a single substrate, pictured here as a holo-


















































Figure 1.12. Displacement mechanism for cell entry. Unlike the canonical pathway, the 
displacement mechanism involves two substrates for the system. An incoming holo-siderophore 
displaces an apo-siderophore already bound to the SBP, then the holo-siderophore that has 


















































Figure 1.13. Shuttle mechanism for cell entry. The setup for the shuttle mechanism is the same as 
the displacement mechanism, in which a holo-siderophore approaches an apo-siderophore already 
bound to the SBP. Instead of displacing the apo-siderophore, the holo-siderophore non-reductively 




















































Figure 1.14. Emergence of catalysis in non-catalytic proteins. The shuttle iron mechanism (top 
left) points to the possibility that FhuD2 plays an enzymatic role in the iron transfer, similar to 
how catalysis has occurred in other proteins including prephenate dehydrogenase (PDB 3KBR), 
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2.1 Preface  
 
 This chapter was adapted with permission from an article of the same title published 
in ACS Infectious Diseases by Nathaniel P. Endicott, Eries Lee and Timothy A. Wencewicz. 
2.2 Abstract  
 
Staphylococcus aureus produces a cocktail of metallophores (staphylopine, staphyloferrin 
A, and staphyloferrin B) to scavenge transition metals during infection of a host. In addition, S. 
aureus displays the extracellular surface lipoproteins FhuD1 and FhuD2 along with the ABC 
transporter complex FhuCBG to facilitate the use of hydroxamate xenosiderophores such as 
desferrioxamine B (DFOB) for iron acquisition. DFOB is used as a chelation therapy to treat 
human iron overload diseases and has been linked to an increased risk of S. aureus infections. We 
used a panel of synthetic DFOB analogs and a FhuD2-selective trihydroxamate sideromycin to 
probe xenosiderophore utilization in S. aureus and establish structure-activity relationships for 
Fe(III) binding, FhuD2 binding, S. aureus growth promotion, and competition for S. aureus cell 
entry. Fe(III) binding assays and FhuD2 intrinsic fluorescence quenching experiments revealed 
that diverse chemical modifications of the terminal ends of linear ferrioxamine siderophores 
influences Fe(III) affinity, but not FhuD2 binding. Siderophore-sideromycin competition assays 
and xenosiderophore growth promotion assays revealed that S. aureus SG511 and ATCC 11632 
can distinguish between competing siderophores based exclusively on net charge of the 
siderophore-Fe(III) complex. Our work provides a roadmap for tuning hydroxamate 
xenosiderophore scaffolds to suppress (net negative charge) or enhance (net positive or neutral 
charge) uptake by S. aureus for applications in metal chelation therapy and siderophore-mediated 




Staphylococcus aureus is a Gram-positive human pathogen responsible for nearly 50% of 
all deaths in US hospitals caused by antibiotic resistant bacteria and fungi (>11,000 deaths per 
year)1. Highly virulent phenotypes of S. aureus, including the methicillin-resistant (MRSA) 
phenotype, are often multi-drug resistant (MDR) and can be community-associated2-4. MRSA 
pathogens rely on a variety of virulence factors to evade the host immune system and enhance 
fitness (Table 2.1)5. Many virulence factors are associated with nutrient acquisition, which is 
central to pathogen proliferation6,7. Nutritional immunity is an important part of the human innate 
immune response to infection8. During an infection, the labile pool of transition metals such as Fe, 
Cu, Ni, Co, Mn, and Zn is restricted and bacterial pathogens must scavenge these scarce nutrients 
to survive9.  
S. aureus produces a cocktail of small molecule metallophores including staphylopine10,11, 
staphyloferrin A12,13, and staphyloferrin B14-16 for transition metal scavenging during infection. 
Staphylopine is a nicotianamine-like metallophore that facilitates Cu(II), Ni(II), Co(II), Zn(II), and 
Fe(II) acquisition10,11. Staphyloferrin A and B are polycarboxylate siderophores with a high 
selectivity for Fe(III)12-16. In addition to endogenous siderophore production, S. aureus can utilize 
heme and xenosiderophores, siderophores pirated from the infection environment, as bioavailable 
sources of Fe(III)6,7. Xenosiderophore utilization by S. aureus confers a special fitness advantage 
by placing the metabolic burden of siderophore biosynthesis on neighboring organisms17,18. 
Natural and semi-synthetic siderophores are attractive chemical scaffolds for medicinal chemistry 
programs aimed at developing metal chelators for treating human diseases including iron 
overload19, cancer20,21, chronic obstructive pulmonary disease (COPD)22, malaria23,24, wound 
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healing25, and Parkinson’s26. Siderophores have also been explored clinically as antibiotic delivery 
agents for treating bacterial infections and medical imaging agents for diagnosing human diseases 
such as cancer and bacterial infections27-29. However, siderophore-based pharmaceutical agents 
have been linked to an increased risk of infection from pathogens that are capable of utilizing the 
siderophore active ingredients as xenosiderophores for iron acquisition in the host30. 
Desferrioxamine B (DFOB), a linear trihydroxamate siderophore produced by Streptomyces 
pilosus, is FDA approved for the treatment of human iron overload diseases and is on the World 
Health Organization’s list of essential medicines19. DFOB use is a predisposing factor for infection 
by bacterial pathogens including S. aureus31, Yersinia enterocolitica32, and Salmonella enterica33, 
which is a leading cause of death in -thalassemia patients receiving frequent blood transfusions. 
There is continued interest in developing new structural analogs of DFOB with improved 
pharmacological properties and in vivo efficacy26. We suggest that investigating xenosiderophore 
utilization of siderophore pharmaceuticals during lead optimization might be a good strategy to 
minimize the risk of infection during human use. 
DFOB utilization in highly virulent S. aureus pathogens has been linked to the fhuBCDG 
genes34, which are under transcriptional regulation by ferric uptake regulator (FUR) DNA-binding 
sequences35. Two copies of the fhuD gene, fhuD1 and fhuD2, are present in S. aureus genomes. 
Both fhuD1 and fhuD2 encode for siderophore-binding surface-displayed lipoproteins36. The ferric 
hydroxamate operon, fhuBCG, encodes for a membrane embedded ATP-dependent transporter 
complex that is required for xenosiderophore active transport34. FhuBG is a permease dedicated to 
xenosiderophore transport, while FhuC is a multi-functional ATPase that interfaces with FhuBG 
and the permeases required for staphyloferrin A and B transport, HtsBC and SirBC, respectively37.  
FhuD1 and FhuD2 bind a diverse set of hydroxamate-containing xenosiderophores including 
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DFOB, ferrichrome, coprogen, and aerobactin38,39. FhuD1 is dispensable for S. aureus growth 
under iron limiting conditions, while FhuD2 is essential for hydroxamate xenosiderophore 
utilization and is a virulence factor for S. aureus that has been exploited for vaccine 
development40,41. CntA10, SirA42, HtsA43, and SstD43 are also surface-displayed lipoproteins 
associated with S. aureus virulence. CntA, SirA, and HtsA bind the endogenous S. aureus 
metallophores staphylopine, staphyloferrin A, and staphyloferrin B, respectively, and SstD binds 
catechol-containing siderophores. S. aureus pathogens are well equipped to utilize hydroxamate, 
-hydroxycarboxylate, and catechol structural classes of siderophores for iron acquisition by 
expressing FhuD1/FhuD2, SirA/HtsA,  and SstD lipoproteins, respectively, along with compatible 
ATP-dependent permeases. 
FhuD1 and FhuD2 are also involved in the transport of hydroxamate-based sideromycins, 
siderophore antibiotic conjugates (SACs), including salmycin, albomycin, ferrimycin, and 
synthetic SACs featuring ferrichrome and DFOB-like siderophore components36,39. Adaptive 
resistance to the salmycins, linear trihydroxamate-aminoglycoside sideromycins produced by 
Streptomyces violaceus, occurs via mutations in fhuD2 leading to antibiotic exclusion44-46. Such 
adaptive resistance is suppressed in mouse models of infection because FhuD2 is essential for 
virulence46. Danoxamine-ciprofloxacin (Dan-Cip) is a synthetic SAC designed to mimic the 
natural salmycins47. The antibiotic activity of Dan-Cip is strongly antagonized in the presence of 
competing trihydroxamate siderophores including DFOB and the parent siderophore danoxamine 
(Dan). FhuD2 is known to tightly bind trihydroxamate siderophores including DFOB and analogs 
thereof with nanomolar affinity suggesting that S. aureus utilization of these molecules as 
xenosiderophores might be nonspecific39. However, DFOB and the corresponding Fe(III) complex 
ferrioxamine B (FOB) more strongly antagonize the antibacterial activity of Dan-Cip than Dan 
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and its Fe(III) complex Dan-Fe suggesting that S. aureus can distinguish between competing 
trihydroxamate siderophores despite the high promiscuity of FhuD2 siderophore binding and the 
structural similarity of DFOB and Dan. 
In this work we systematically explored the structural basis for hydroxamate 
xenosiderophore utilization by human pathogenic S. aureus using a rationally designed panel of 
synthetic DFOB and Dan analogs (SDFOB and compounds 1–17; Fig. 2.1). We utilized Dan-Cip 
as a chemical probe for xenosiderophore utilization in S. aureus SG511. We measured the apparent 
Fe(III) affinity constants (KFe), apparent FhuD2 binding constants (Kd), and S. aureus SG511 
minimum inhibitory concentrations (MICs) in the presence of competing Dan-Cip for all members 
of the trihydroxamate siderophore panel (Table 2.2). We found that net siderophore charge is the 
most important physiochemical property for determining xenosiderophore utilization by S. aureus 
SG511 and S. aureus ATCC 11632. The structure-function relationships described in this work 
will help to guide the development of siderophore-based molecules for applications in medical 
imaging and the treatment of iron overload and infectious diseases48. 
2.4 Results and Discussion  
Design and Synthesis of a Ferrioxamine Siderophore Library 
Dozens of naturally occurring trihydroxamate ferrioxamine siderophores are reported in 
the chemical literature49. Ferrioxamine siderophores are biosynthesized by a non-ribosomal 
peptide synthetase-independent pathway using alternating succinic acid and N-hydroxy-
cadaverine or N-hydroxy-putrescine units50-52. The spacing between hydroxamate metal chelating 
groups governed by the succinate and cadaverine units is ideal for chelating Fe(III) in a stable 1:1 
siderophore:metal complex with octahedral geometry53,54. Natural and synthetic structural variants 
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of DFOB are commonly modified at the amino terminus49. Acylation of the DFOB primary amine 
decreases water solubility, slows clearance of iron from human blood, and increases intracellular 
iron sequestration in human cell lines55,56. Microbes produce structural variants of ferrioxamine 
siderophores to gain an evolutionary advantage through selective siderophore uptake, quorum 
sensing, growth promotion, or growth suppression of neighboring microbes17,18,57,58. Siderophore 
acylation has also been shown to promote self-assembly in aqueous environments, enhance 
membrane affinity, and promote surface adhesion59-62. We synthesized a library of ferrioxamine 
siderophores built on repeating succinic acid and N-hydroxy-cadaverine units to probe the effects 
of polarity, net charge, and sterics on Fe(III) affinity, FhuD2 binding, and S. aureus utilization 
(Fig. 2.1 and Fig. 2.2–2.4)63,64. 
DFOB is a linear trihydroxamate siderophore with free amine and N-acetyl termini and a 
net charge of +1 when bound to Fe(III)53. Reaction of DFOB with succinic anhydride gives 
SDFOB with a net charge of -1 when bound to Fe(III)65. Dan also carries a net negative charge 
and is found as the naturally occurring siderophore portion of the salmycin sideromycins, which 
are biosynthesized from three units of succinate, two units of N-hydroxy-cadaverine, and one unit 
of N-hydroxy-5-amino-1-pentanol66. We completed a total synthesis of Dan and analogs 1-16 
using a previously reported benzyl protecting group strategy (Scheme 2.1)45,47,63,64,67,68. Dan and 
analogs 1–4 have a hydroxyl and carboxyl termini and a predicted net charge of -1 when bound to 
Fe(III). We also prepared methyl esters 5–9, amides 10 and 11, sulfonamides 12 and 13, acetylated 
analog 14, and alcohol 15 as charge neutral variants. Analog 16 has an amine terminus and will 
have a net +1 charge when bound to Fe(III). We synthesized a charge neutral macrocyclic analog 




Side Chains Influence Kinetic and Thermodynamic Fe(III) Complex Stability 
 We used an EDTA metal exchange assay to measure the apparent Fe(III) affinity constants 
(KFe) of DFOB, Dan, SDFOB, Dan-Cip and analogs 1–17 at pH 7.4 (Fig. 2.5; Table 2.2; Fig. 
2.6)69. All the siderophore-Fe(III) complexes were purified by recrystallization and showed a 
distinct max optical absorbance between 420-430 nm with extinction coefficients of ~3000 M-1cm-
1. A solution of each siderophore-Fe(III) complex at 0.1 M in pH 7.4 buffer (10 mM HEPES, 600 
mM NaCl, 100 mM KCl) in a 1 cm cuvette gave a starting absorbance of 0.1-0.2 units. Solutions 
were treated with 1.2 equivalents of EDTA and monitored continuously by optical absorbance at 
430 nm for 90 min or until equilibrium was reached. DFOB had the highest affinity for Fe(III), 
KFe = 1030.3; a value consistent with previous literature reports70,71. SDFOB showed a 10-fold 
decrease in Fe(III) affinity, KFe = 1029, relative to DFOB. Changing the primary amine of DFOB 
to a primary alcohol in analog 16 resulted in a reduction of Fe(III) binding affinity by four orders 
of magnitude (KFe = 1026.3). We measured KFe values ranging from 1026–1028 for Dan, Dan-Cip, 
and analogs 1–15, which all have a primary alcohol terminus (Fig. 2.5c). The primary amine of 
DFOB is protonated at pH 7.4, while the primary alcohol of Dan and analogs 1-16 is free to 
interact with the oxophilic Fe(III) and might destabilize the metal complex through intramolecular 
ligand displacement70. Macrocyclization of siderophores is known to increase KFe by 
preorganizing the ligands for metal chelation69. The KFe value for desferrioxamine E, a 
macrolactam trihydroxamate siderophore, was reported to be 1032.5, which is a 100-fold increase 
in KFe compared to linear DFOB. In contrast, macrolactone 17 had ~100-fold lower Fe(III) affinity, 
KFe = 1025.4, than linear Dan suggesting that forcing ester closer the Fe(III) center through 
macrocyclization destabilizes the metal complex.   
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 Siderophore side chain substituents can interact with the Fe(III) metal center. The relative rate 
of methyl ester hydrolysis for the Fe(III) complexes of siderophores 5–8 at pH 10 increases with 
proximity of the methyl ester to Fe(III) (t1/2: 5 > 6 > 7 > 8) suggesting that the Fe(III) interacts 
with the ester as a Lewis acid or participate in water activation during hydrolysis64. The rate 
limiting step of Fe(III) release from a trihydroxamate siderophore-Fe(III) complex is dissociation 
of the first hydroxamate ligand through water displacement on the Fe(III) center70. We found that 
the Fe(III) complexes of Dan, Dan-Cip, and analogs 1–17 were more kinetically labile than FOB 
in the EDTA metal exchange assay (Fig. 2.5b; Fig. 2.6,2.7). The primary alcohol might displace 
the first hydroxamate ligand in an intramolecular reaction to speed up dissociation of Fe(III) from 
the siderophore during metal exchange with EDTA70. 
Side Chains do not Influence FhuD2 Binding 
 We recombinantly expressed the soluble siderophore-binding domain of S. aureus FhuD2 with 
an N-terminal hexahistadine tag. We purified N-His6-FhuD2 by Ni-NTA affinity chromatography 
(Fig. 2.8; Tables 2.3,2.4). We used an intrinsic fluorescence quenching assay to assess whether N-
His6-FhuD2 can bind DFOB, FOB, Dan, Dan-Fe, as well as the Fe(III) complexes of SDFOB, 
Dan-Cip, and analogs 1-17 (Fig. 2.9a; Table 2.2)72. FhuD2 is known to bind the iron-free, DFOB, 
and iron-bound, FOB, forms of trihydroxamate siderophores72,73. We observed dose-dependent 
fluorescence quenching when treating N-His6-FhuD2 with iron-free, DFOB and Dan, and iron-
bound, FOB and Dan-Fe, trihydroxamate siderophores (Fig. 2.9b). The apparent dissociation 
constants for DFOB (Kd = 90.7  11.9 nM) and Dan (Kd = 70.5  11.1 nM) were ~2-fold higher 
than the corresponding Fe(III) complexes FOB (Kd = 48.4  6.6 nM) and Dan-Fe (Kd = 39.4  2.9 
nM) (Table 2.2).  The fluorescence of purified recombinant N-His6-FhuD2 from S. aureus was 
quenched in a dose dependent manner by all of the siderophores in our panel (Fig. 2.9c; Fig. 2.10). 
53 
 
Apparent dissociation constants (Kd) ranged from 39–189 nM regardless of Fe(III) affinity, side 
chain polarity, steric bulk, or net siderophore charge. Attachment of ciprofloxacin, a 
fluoroquinolone antibiotic, to the succinyl terminus of Dan did not significantly impact FhuD2 
binding (Kd for Dan-Cip = 93.9  23.5 nM). Our results confirm that FhuD2 is a promiscuous 
ferrioxamine siderophore-binding protein in pathogenic S. aureus. 
Net Siderophore Charge Influences Xenosiderophore Utilization by S. aureus 
We used a siderophore-sideromycin competition assay to assess xenosiderophore 
utilization by S. aureus SG511 (Fig. 2.11; Table 2.2)47. We used the broth microdilution method 
for MIC determination to quantitatively assess the ability of the iron-free and Fe(III)-bound forms 
of siderophores DFOB, Dan, SDFOB, and 1–16 to antagonize the antibacterial activity of iron-
free Dan-Cip against S. aureus SG511 under iron deficient media conditions (Meuller-Hinton 
broth No. 2 supplemented with 2,2’-dipyridyl). Dan-Cip alone gave an MIC value of 1 M against 
S. aureus SG511. None of the iron-free or Fe(III)-bound siderophores inhibited the growth of S. 
aureus SG511. We measured MIC values for 1:1 stoichiometric ratios of Dan-Cip:competing 
siderophore. MIC values  4 M were judged to be a result of the competing siderophore 
antagonizing the active transport Dan-Cip to the cytoplasm of S. aureus SG511 where the DNA 
gyrase target of the fluoroquinolone antibiotic resides74. Despite the ability of FhuD2 to bind all 
siderophores with nanomolar affinity, we observed that only siderophores with a net positive 
charge (DFOB and 16) or neutral charge (5, 6, and 8–14) antagonized the growth inhibitory 
activity of Dan-Cip towards S. aureus SG511. Siderophores with a net negative charge (Dan, 
SDFOB, 1–4) had no effect on Dan-Cip activity when supplemented in the iron-free and Fe(III)-
bound forms. DFOB and siderophore 10 were the most antagonistic towards the antibacterial 
activity of Dan-Cip, giving MIC values  128 M in both the iron-free and Fe(III)-bound forms. 
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The preformed Fe(III) complexes of siderophores 5–9 and 11–16 (MIC values  64–128 M) were 
better antagonists than the iron-free forms (MIC values  16–64 M) in the Dan-Cip competition 
assay (Table 2.2; Fig. 2.11b, 2.11c). There was no apparent correlation between antagonism of 
Dan-Cip antibacterial activity and siderophore KFe, apparent Kd for FhuD2, or kinetic stability of 
the siderophore-Fe(III) complex. 
We confirmed that antagonism of Dan-Cip antibacterial activity was a direct result of 
transport competition by analyzing S. aureus ATCC 11632 growth curves under highly growth 
restrictive iron limiting conditions with siderophore supplementation (Fig. 2.12; Fig. 2.13). The 
growth of S. aureus ATCC 11632 was severely halted at 37 C over an 84-hour growth period in 
TMS minimal media treated with 200 M 2,2’-dipyridyl. We evaluated the ability of FOB (net +1 
charge), Dan-Fe (net -1 charge), 5-Fe (charge neutral), and 16-Fe (net +1 charge) to rescue the 
growth of S. aureus ATCC 11632. FOB boosted S. aureus ATCC 11632 growth starting at a 
concentration of 5 M with full growth recovery observed starting at 20 M. Siderophores 16-Fe, 
5-Fe, and Dan-Fe promoted S. aureus ATCC 11632 growth at 40 M, 80 M, and 320 M, 
respectively. Figure 5 compares growth curves for S. aureus ATCC 11632 in the presence of 1.28 
mM FOB, Dan-Fe, 5-Fe, and 16-Fe and highlights the preference for utilization of the positively 
charged siderophores FOB and 16-Fe over neutral and charge negative siderophores 5-Fe and 
Dan-Fe, respectively, which is consistent with the trend for siderophore transport observed in the 





2.5 Further Discussion and Conclusions 
  X-ray crystal structures of FhuD2 and other siderophore binding proteins show that amino 
acid residues in the ligand binding site do not make direct contacts to the Fe(III) metal center of 
bound siderophore-Fe(III) complexes75. Specificity for siderophore ligands arises from non-
covalent interactions with the metal chelating groups and the siderophore backbone. Tris-catechol 
binding surfaces are typically rich in positively charged amino acid side chains to accommodate 
the net -3 charge of a tris-catecholate Fe(III) complex76. Polycarboxylate ligand binding sites also 
present a positively charged platform to ensure favorable electrostatics upon siderophore 
binding77. HtsA binds staphyloferrin A using nine siderophore-interacting residues including six 
arginines, one tyrosine, one histidine, and one lysine77,78. SirA binds staphyloferrin B using similar 
ionic interactions79. FhuD2 presents a charge neutral surface suitable for binding positively 
charged, negatively charged, and charge neutral ferrioxamine siderophores (Fig. 2.14)38.  
  HtsA and SirA undergo large conformational changes upon binding the endogenous S. 
aureus siderophores staphyloferrin A and staphyloferrin B, respectively78,79. Electrostatic 
interactions play an important role in HtsA and SirA siderophore binding77. FhuD2 undergoes a 
modest conformational change upon siderophore binding that might enable broad utilization of 
hydroxamate-based xenosiderophores38. The charge neutral siderophore binding pocket 
accommodates positively charged, negatively charged, and charge neutral hydroxamate 
siderophores. Although FhuD2 is promiscuous for binding hydroxamate siderophores, our results 
suggest that other cellular factors play a role in xenosiderophore utilization. S. aureus SG511 
showed a strong preference for transporting positively charged and charge neutral trihydroxamate 
siderophores over negatively charged analogs in siderophore-sideromycin competition assays 
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(Fig. 2.11). The same preference for siderophore charge was also observed in growth promotion 
assays using S. aureus ATCC 11632 (Fig. 2.12). We propose that xenosiderophore utilization in 
S. aureus depends primarily on net siderophore charge and is not influenced by FhuD2 affinity, 
Fe(III) affinity, or kinetic stability of the siderophore-Fe(III) complex.  
  The origin of charge preference for trihydroxamate xenosiderophore utilization by S. 
aureus is unclear. One explanation could be that the S. aureus cell envelope carries a strong net 
negative charge due to the high density of phosphatidylglycerol80,81 and teichoic acids82-84. The net 
negative charge of the S. aureus cell envelope depends on the number of lysyl-
phosphotidylglycerol molecules and D-Ala teichoic acid esters. Teichoic acids, 
phosphotidylglycerols, and cell envelope charge play roles in virulence, biofilm formation, cell 
adhesion, motility, antibiotic permeability, and antibiotic resistance85,86. We hypothesize that the 
negatively charged S. aureus cell envelope electrostatically repels negatively charged 
xenosiderophores, which decreases the local concentration of xenosiderophores around the S. 
aureus lipid membrane. Adaptive resistance to the salmycins suggests that FhuD2 is the primary 
receptor for trihydroxamate xenosiderophores in S. aureus44. Therefore, it is unlikely that an 
alternate siderophore-binding protein is responsible for the charge preference of xenosiderophore 
utilization. Results from the siderophore-sideromycin competition assay suggest that the 
ferrioxamine xenosiderophores used in this study were in direct competition for transport with 
Dan-Cip, which we presume depends on FhuD2 for cell entry much like the structurally related 
salmycins44. 
  A better understanding of siderophore membrane transport paradigms is critical for 
rationalizing xenosiderophore utilization in S. aureus pathogens87. Two membrane transport 
paradigms based on shuttle and displacement mechanisms have been proposed72,73,88. In the 
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siderophore shuttle mechanism the siderophore receptor first binds to Fe-free siderophore and 
catalyzes iron exchange from a second siderophore-Fe(III) complex prior to influx. Direct 
evidence for the siderophore shuttle mechanism has been obtained using recombinant YxeB from 
B. subtilis as a catalyst for Fe(III) exchange between DFOB and acetylferrioxamine B72,73. In the 
siderophore displacement mechanism metal free siderophore bound to receptor is displaced by an 
incoming siderophore-Fe(III) complex that gains cell entry. Our results support that the 
displacement mechanism is possible. FhuD2 binds negatively charged trihydroxamate 
siderophores with nanomolar affinity. Charge negative xenosiderophores, such as Dan, 
moderately promote S. aureus ATCC 11632 growth under iron restrictive conditions. However, 
charge negative siderophores fail to gain cell entry when in competition with Dan-Cip, a charge 
neutral sideromycin. Hence, the measured dissociation constants of FhuD2 for siderophores are 
not fully predictive of xenosiderophore utilization. FhuD2 complexes with negatively charged 
siderophores might be kinetically labile leading to a preference for displacement mechanisms 
when competing with positively charged or charge neutral siderophores that might have an 
increased dwell time on FhuD289. 
  Our work suggests that the structure of linear ferrioxamine siderophores can be optimized 
through modification of the termini to suppress or enhance xenosiderophore utilization by S. 
aureus and other pathogens that express FhuD2 as a virulence factor (Fig. 2.10). Suppression of 
xenosiderophore utilization by pathogenic bacteria is desirable for use of siderophores as 
treatments for iron overload diseases. DFOB and other metal chelators including deferasirox and 
deferiprone are widely used to treat human iron overload diseases19,90. There is growing interest in 
developing new metal chelators, including structural variants of DFOB, that show improved 
efficacy and better patient compliance (DFOB is administered via infusion pump leading to low 
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patient compliance)26. DFOB and related trihydroxamate siderophores also show promise as 
possible therapeutic agents for treating malaria23,24, cancer20,21, diseases associated with 
ferroptosis91, COPD22, renal protection92, and neurological disorders such as Parkinson’s26. DFOB 
use has been linked to an increased risk of infection, a leading cause of death in thalassemia major 
patients31-33. New structural variants of DFOB are needed to fully explore the increasing number 
of new medical applications for siderophore-based chelation therapies48. Our work serves as a 
starting point for optimizing the DFOB structure to hinder xenosiderophore utilization by potential 
bacterial pathogens such as S. aureus while maintaining a high-affinity for Fe(III). Hindering 
xenosiderophore utilization by human pathogens might decrease the risk of infection during 
administration of siderophore-based chelation therapies30.  Conversion of the DFOB primary 
amine to a primary alcohol results in a 100-fold decrease in KFe, which might decrease the 
efficiency of iron clearance during chelation therapy and still enables xenosiderophore utilization 
by S. aureus. Succinylation of the amino terminus gives SDFOB, which suffers a smaller 10-fold 
decrease in KFe and hinders xenosiderophore utilization by pathogenic S. aureus. Future efforts to 
improve ferrioxamine siderophores for medical applications in metal chelation-based therapies 
should focus on structural modifications that make net siderophore charge negative and avoid 
oxophilic terminal functional groups near the Fe(III) metal center to maintain high KFe and provide 
maximum kinetic stability of the siderophore-Fe(III) complex. To enhance ferrioxamine 
xenosiderophore utilization by S. aureus for potential diagnostic and antibiotic delivery 
applications the net siderophore charge should be neutral or positive. Steric bulk close to the Fe(III) 
metal center decreases KFe so linkers should be used to provide enough space between the 
siderophore and molecular cargo to optimize metal chelation and receptor binding.  
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  Our results support the need for more functional xenosiderophore selection screens using 
bacterial pathogens to inform the use of siderophores in medical and environmental applications93-
98. Competition with environmental xenosiderophores and endogenous siderophores produced by 
the pathogen of interest must be considered. To ensure efficacy and block adaptive resistance 
during siderophore applications in antibiotic delivery, it is imperative that the siderophore delivery 
vector outcompetes endogenous pathogen siderophores and that siderophore transport proteins are 
required for virulence27,99. FhuD2 is required S. aureus virulence and we show that ferrioxamine 
siderophores can be structurally tuned for transport based on net charge. FhuD2 promiscuously 
binds ferrioxamine siderophores and we found that siderophore receptor binding alone is not 
predictive of xenosiderophore utilization and membrane transport. Here we showed that 
sideromycins (siderophore-antibiotic conjugates) can be used as chemical probes for evaluating 
xenosiderophore utilization by pathogens of interest. Siderophore-sideromycin competition assays 
can be used to establish structure-function relationships that will guide the design of improved 
siderophore-based metal chelation therapies and pathogen-targeted sideromycin antibiotics.  
2.6 Materials and Methods 
Strains, Materials, and Instrumentation 
Siderophore-sideromycin competition assays and bacterial growth promotion studies were 
performed with S. aureus SG511 (kindly provided by Dr. Ute Möllmann) and S. aureus ATCC 
11632, respectively (Table 2.5). All media and buffers were prepared using distilled deionized 
H2O. All bacterial cells were stored at –80 C as glycerol stocks and transformations were 
performed via electroporation using a MicroPulser Electroporator (Bio-Rad). All siderophores and 
sideromycins used in this study were synthesized as described previously47,63,64 and obtained 
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through a material transfer agreement with the University of Notre Dame (Scheme 2.1). DFOB 
was purchased from Sigma-Aldrich (St. Louis, MO). The pET28-fhuD2 plasmid was codon 
optimized, sequenced, and cloned for protein expression in E. coli BL21 (DE3) by GenScript. E. 
coli TOP10 cells were purchased from Invitrogen and E. coli BL21-Gold(DE3) cells were 
purchased from Agilent. Nickel-nitrilotriacetic acid (Ni-NTA) agarose was purchased from 
Invitrogen. Any kD SDS-PAGE gels were purchased from Bio-Rad. All buffers, salts, and 
chemical reagents were purchased from Sigma-Aldrich, unless otherwise stated. All pH 
measurements were recorded on an Orion Star A111 pH meter and a PerpHecT Ross micro pH 
electrode from ThermoFisher. Bacterial growth curves were measured using a Molecular Devices 
SpectraMax Plus 384 plate reader using sterile round-bottom polystyrene 96-well plates with 
sterile polystyrene lids. Optical absorbance spectroscopy was performed on a Cary 50 with 
autosampler and water Peltier thermostate using methacrylate cuvettes.  
Determination of KFe 
Apparent siderophore Fe(III) affinity values (KFe) were measured using an EDTA 
competition experiment according to a literature protocol69. Pure siderophore-Fe(III) complex 
(Dan-Fe, FOB, SFOB, Dan-Cip-Fe, 1-Fe–17-Fe) was dissolved in pH 7.4 HEPES buffer (10 mM 
HEPES, 600 mM NaCl, 100 mM KCl) to a final concentration of 0.1 µM and treated with 1.2 
equivalents of EDTA to give a total volume of 1 mL. The mixture was analyzed continuously for 
90 min, or until equilibrium was reached, at 1 scan/s by optical absorbance spectroscopy at 430 
nm in a methacrylate cuvette. The absorbance at 430 nm decreased over time for each siderophore-
Fe(III) complex with pseudo first-order kinetics. Iron(III) exchange t1/2 values were calculated by 
fitting the exponential decay plots to a pseudo first-order rate equation using GraphPad Prism 
version 7.0b (Fig. 2.6,2.7). The decrease in absorbance at 430 nm correlates directly with exchange 
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of Fe(III) from the siderophore to EDTA. Siderophore KFe values were calculated from the 
difference in absorbance at 430 nm before and after addition of EDTA as described previously 
(Equations 2.1–2.11)69. An extinction coefficient of 3000 M-1 cm-1 was used for all siderophore-
Fe(III) complexes. A KFe value of 1025.1 was used for EDTA at pH 7.4 in all calculations49,100. All 
experiments were performed in triplicate as independent trials. 
Purification of N-His6-FhuD2 
A 5 mL culture of E. coli BL21-Gold(DE3) containing the pET28a-fhuD2 plasmid was 
grown overnight in LB containing 50 g/mL kanamycin with agitation at 37 C. A 200 L aliquot 
was used to inoculate 500 mL of terrific broth (12 g/L tryptone, 24 g/L yeast extract, 5 g/L glycerol, 
17 mM KH2PO4, 72 mM K2HPO4) containing 50 g/mL kanamycin. The culture was grown at 37 
C with shaking until the OD600 reached ~0.4. The culture was cooled on ice and protein expression 
was induced by addition of 500 L of a sterile 0.5 M aqueous solution of IPTG. The culture was 
shaken at 15 C for 18 hrs and cells were isolated by centrifugation (5,000 rpm, 20 min, 4 C). The 
cell pellet was washed and suspended in 40 mL of cold lysis buffer (50 mM K2HPO4, 500 mM 
NaCl, 5 mM -mercaptoethanol, 20 mM imidazole, 10% glycerol, pH 8). The cell suspension was 
flash frozen, thawed, and lysed by two passages through an Emulsiflex C5 cell disruptor (Avestin). 
Cell lysate was clarified by ultracentrifugation (45,000 rpm, 35 min, 4 C) and the supernatant was 
treated with Ni-NTA resin and rocked gently for ~30 min. The flow-through was discarded and 
the Ni-NTA resin was washed twice with cold lysis buffer (40 mL) and eluted five times with 10 
mL aliquots of elution buffer (50 mM K2HPO4, 500 mM NaCl, 5 mM -mercaptoethanol, 300 mM 
imidazole, 10% glycerol, pH 8). Elution fractions were analyzed by SDS-PAGE with Coomassie 
blue visualization (Fig. 2.7). Fractions containing pure N-His6-FhuD2 were combined and dialyzed 
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overnight in 1.8 L phosphate buffer (50 mM K2HPO4, 150 mM NaCl, 1 mM DTT, pH 8) using 
10,000 MWCO SnakeSkin dialysis tubing (ThermoFisher). Protein was concentrated by 
centrifugal filtration using a 10,000 MWCO membrane (Amicon Ultra 15 mL; EMD Millipore), 
flask frozen in liquid nitrogen as 50 L aliquots and stored at -80 C at a final concentration of 1.8 
mM. 
FhuD2 Binding Studies 
N-His6-FhuD2 was recovered from a -80 C freezer stock and thawed on ice. Stock protein 
solutions at 5.4 M were prepared in TBS buffer (25 mM Tris-HCl, 8 g/L NaCl, 0.2 g/L KCl, pH 
7.4) and diluted 1:50 in TBS buffer to acquire ~100 nM solutions of N-His6-FhuD2 for 
fluorescence quenching assays72,73. Stock solutions of siderophores (DFOB, FOB, SFOB, Dan, 
Dan-Fe, Dan-Cip-Fe, and 1-Fe–17-Fe) were prepared in H2O at 2 mM. Increasing concentrations 
of siderophore (final siderophore concentrations: 0 nM, 26.7 nM, 53.2 nM, 79.5 nM, 105.6 nM, 
171 nM, 299 nM, 422 nM, 881 nM) were added to a solution of N-His6-FhuD2 (~100 nM final 
concentration) in TBS buffer (final volume was 300 L). The maximum fluorescence of each 
siderophore/N-His6-FhuD2 solution was measured (typically at ~340 nm) in a HellmaAnalytics 
High Preceision Cell cuvette made of Quartz SUPRASIL (light path was 10 x 2 mm) using a 
PerkinElmer LS 55 Luminescence Spectrometer (emission analyzed at 300–400 nm with an 
excitation  of 280 nm, emission slits set to 10 nm, and a scan speed of 400 nm/min). Fluorescence 
intensity versus siderophore concentration was plotted and the apparent Kd of N-His6-FhuD2 for 
each siderophore was calculated by nonlinear regression using a one binding site model in 




Siderophore-Sideromycin Competition Assay 
Assay was performed as described previously47. Minimum inhibitory concentrations 
(MICs) were measured using the broth microdilution method following the Clinical and 
Laboratory Standards Institute (CLSI) guidelines101. Each well of a 96-well plate was filled with 
50 L of sterile Mueller-Hinton No. 2 (MHII) broth made Fe-deficient with 2,2-dipyridyl (0.8 mL 
of a 1 mg/mL filter sterilized aqueous solution of 2,2’-dipyridyl added to 49.2 mL of sterile MHII 
broth). Equimolar solutions of Dan-Cip and each siderophore (DFOB, FOB, SDFOB, SFOB, 
Dan, Dan-Fe, 1–6, 8–16, 1-Fe–6-Fe, and 8-Fe–16-Fe) were prepared at 512 M in sterile Fe-
deficient MHII broth. 50 L of the compound solutions were added to the first well of the 96-well 
plate and diluted two-fold down each row. 50 L of S. aureus SG511 inoculum (5 x 105 cfu/mL 
in MHII broth) was added to each well giving a final volume of 100 L/well and a concentration 
range of 128–0.0625 M for each test compound. Plates were covered with lids and incubated at 
37 C for 18 hrs. The MIC was judged to be the lowest concentration (M) of compounds 
inhibiting visible bacterial growth relative to a DMSO or H2O control. Ciprofloxacin was included 
as a positive control at a concentration range of 32– 0.0156 M and gave a recorded MIC of 0.5 
M. 
S. aureus Growth Studies 
A fresh overnight culture of S. aureus ATCC 11632 was grown in sterile LB broth at 37 
C from frozen glycerol stocks. A 0.5 McFarland standard102 (OD600 ~0.8–1) was prepared as the 
plate inoculum in filter sterilized, Fe-deficient TMS media (12.1 g/L Tris-base, 16.6 g/L succinic 
acid, 10 g/L casamino acids, 40 mL of salt solution (14.5 g NaCl, 9.25 g KCl, 2.75 g NH4Cl, 3.55 
g cysteine, 4.23 g thiamine, 0.31 g nicotinic acid, 2.5 mg biotin, 23.9 g MgCl2, 2.78 g CaCl2 in 100 
64 
 
mL H2O), and 200 M 2,2’-dipyridyl, pH 7.4)16. Each well of a sterile 96-well plate was filled 
with 50 L of TMS media. 50 L of siderophore (FOB, Dan-Fe, 5-Fe, or 16-Fe) in sterile TMS 
media was added to the first column of the plate at a final concentration of 2560 M. Siderophores 
were diluted two-fold down the plate and each well of the plate was then treated with 50 L of 
inoculum to give final siderophore concentrations of 1280–1.25 M for FOB and Dan-Fe. 
Siderophores 5-Fe and 16-Fe were analyzed at final concentrations of 1280–40 M. Plates were 
covered with sterile lids and incubated at 37 C. The final volume of each well was 100 L. The 
OD600 of each well was measured continuously over 90 hrs using a SpectraMax Plus 384 
Microplate Reader (Fig. 2.16). Plates were agitated prior to measurement of OD600 and each 
growth curve was generated in triplicate against a TMS media control. 
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2.6 Tables and Figures 
 
 
Table 2.1. Known iron acquisition virulence factors and associated genes in S. aureus pathogens.1 
 
Iron Source S. aureus Genes 
Heme Binding, extraction, and import isdAB, isdH, isdCDEF, srtB, srtA 
Degradation isdG, isdI, iruO 
Sensing and export hssRS–hrtAB 
Endogenous siderophores Staphyloferrin A, Staphyloferrin B 
Synthesis and export Staphyloferrin A: sfaABC, sfaD 
Staphyloferrin B: sbnA–I 
Import and iron release Staphyloferrin A: htsABC 
Staphyloferrin B: sirABC 
Xenosiderophores Desferrioxamine B, ferrichrome, aerobactin, 
coprogen 
Hydroxamate fhuBGC2, fhuD1, fhuD2 
Catecholate sstABCD 
Inorganic Iron (ferrous iron transport proteins) feoAB, fepABC 
Major transcriptional regulator fur 











Figure 2.1. Chemical structures of S. aureus xenosiderophores and sideromycins utilized in this 
work. Siderophore backbones are shown in black, metal chelating groups are shown in red, and 
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Table 2.2. Net charge, apparent log KFe values, MIC values for siderophore-sideromycin 
competition, and apparent FhuD2 Kd values for ferrioxamine siderophores. aLog KFe values were 
determined by an EDTA competition assay using optical absorbance spectroscopy, and standard 
deviations were determined from three independent experiments. bMIC values were against S. 
aureus SG511 using a 1:1 molar ratio of Dan-Cip and the competing siderophore-Fe(III) complex 
(FOB, Dan-Fe, SFOB, or 1-Fe–17-Fe). MICs were determined in triplicate using the broth 
microdilution method in MHII media containing 2,2-dipyridyl following the CLSI guidelines. 
cMIC values represent a 1:1 molar ratio of Dan-Cip and the competing siderophore (DFOB, Dan, 
SDFOB, or 1–17).  dFhuD2 Kd values were determined by fluorescence quenching, and standard 
deviations were determined from at least three independent experiments. Kd value is for the 
siderophore-Fe(III) complex. eKd value is for the Fe–free siderophore. 
Siderophore 
Net Charge at 
pH 7.4 
log KFea MIC w/ Fe (M)b MIC w/o Fe (M)c FhuD2 Kd (nM) 
DFOB +1 30.3  0.4 >128 128 
48  7d 
91  12e 
Dan -1 27.8  0.3 1 1 
39  3d 
71  11e 
SDFOB -1 29.0  0.1 0.5 0.5 67  13d 
Dan-Cip 0 25.6  0.1 1 N/A 94  24d 
1 -1 27.9  0.2 1 1 78  10d 
2 -1 28.0  0.1 1 1 125  43d 
3 -1 26.0  0.1 1 1 N/A 
4 -1 25.6  0.2 2 2 152  81d 
5 0 27.7  0.1 128 16 193  23d 
6 0 26.1  0.2 128 32 46  12d 
7 0 27.5  0.1 N/A N/A 46  6d 
8 0 28.2  0.1 128 64 114  23d 
9 0 28.2  0.3 128 32 102  21d 
10 0 27.9  0.1 128 64 55   10d 
11 0 27.4  0.1 64 32 70  13d 
12 0 27.3  0.1 64 32 65  13d 
13 0 28.0  0.1 128 64 49  10d 
14 0 26.3  0.5 128 64 71  17d 
15 0 25.7  0.2 64 16 189  53d 
16 +1 27.2  0.1 >128 128 76   11d 
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Figure 2.5. Siderophore side chains influence the kinetic and thermodynamic stability of 
siderophore-Fe(III) complexes. (a) Scheme depicting an EDTA competition assay for determining 
siderophore KFe values and Fe(III) exchange kinetics. (b) Graph depicting the percentage of 
siderophore-Fe(III) complex remaining as a function of time after treatment with 1.2 equivalents 
of EDTA at pH 7.4. The percentage of siderophore-Fe(III) complex was determined by optical 
absorbance spectroscopy with continuous scanning at 430 nm. The grey shaded area above and 
below the curve represents standard deviations for three independent experiments. (c) Bar graph 
depicting KFe values for all siderophores used in this study. Error bars represent standard deviations 

























































































































Figure 2.6a. Exponential decay plots for EDTA iron(III) binding competition assay with 




     
Figure 2.6b. Exponential decay plots for EDTA iron(III) binding competition assay with 
ferrioxamine siderophores. Error bars represent standard deviations for at least three independent 
trials. 






















































































































Figure 2.6c. Exponential decay plots for EDTA iron(III) binding competition assay with 






Figure 2.7. Iron(III) exchange half-lives (t1/2) between ferrioxamine siderophores and EDTA in 
pH 7.4 buffer at room temperature determined from first-order rate plots. The t1/2 for FOB was too 
slow to measure an accurate first-order rate. Error bars represent standard deviations from the mean 











































































Figure 2.8. SDS-PAGE analysis of purified N-His6-FhuD2. SDS-PAGE gel (Any kD, Bio-Rad) 
was loaded with protein ladder (ThermoFisher PageRuler Prestained Protein Ladder 10–180 kDa) 
in lane 1, Ni-NTA column flow through in lane 2, N-NTA column washes in lanes 3 and 4, and 
Ni-NTA elutions in lanes 5–9. Gels were stained with Coomassie blue and photagraph. Image on 






Figure 2.9 Siderophore side chains weakly influence FhuD2 binding. (a) Scheme depicting the 
equilibrium (Kd) for siderophore-FhuD2 complex stability. (b) Graph depicting dose-dependent 
fluorescence quenching (excitation = 280 nm; emission ~ 340 nm) of N-His6-FhuD2 by DFOB, FOB, 
Dan, and Dan-Fe used to calculate the apparent Kd values. Error bars represent standard deviation 
for three independent experiments at each indicated concentration of siderophore. (c) Bar graph 
depicting apparent N-His6-FhuD2 Kd values for all siderophores used in this study. Error bars 

























































































































Table 2.3. Primary protein sequences of wild type FhuD2 from S. aureus and the truncated N-
His6-FhuD2 used here in fluorescence quenching assays. 














aPre-lipoprotein signal sequence highlighted in magenta. Soluble siderophore-binding domain 
highlighted in teal. bHexahistidine motif with thrombin cleavage site highlighted in yellow. 
Soluble siderophore-binding domain highlighted in teal. 
Table 2.4. Codon optimized nucleotide sequence of FhuD2-N-His6 from S. aureus that was cloned 





















Figure 2.10. Summary of ferrioxamine xenosiderophore structure-function relationships 


















Hydroxamates critical for Fe(III) chelation.
R1 functionalization influences KFe and utilization by S. aureus.
R1 = OH lowers KFe; R1 = NH2 increases KFe and S. aureus utilization.
R2 functionalization influences KFe and utilization by S. aureus.
R2 = carboxylic acid decreases S. aureus utilization.
R2 = ester, amide, sulfonamide, alkyl, hydroxy ethyl, and amino 
ethyl increases S. aureus utilization relative to COOH.





Figure 2.11. Net siderophore charge strongly influences utilization by S. aureus SG511. (a) 
Scheme depicting a siderophore-sideromycin competition MIC assay used to evaluate 
xenosiderophore utilization by S. aureus SG511. An equimolar mixture of siderophore and 
sideromycin are used for MIC determination. If the sideromycin is transported a low MIC 
value is observed. If the siderophore is transported a high MIC is observed. (b) S. aureus 
SG511 MIC values for 1:1 mixtures of iron-free siderophore and iron-free sideromycin Dan-
Cip. (c) S. aureus SG511 MIC values for 1:1 mixtures of Fe(III)-bound siderophores and iron-
free sideromycin Dan-Cip. All MICs were determined in triplicate. The standard error of an 
MIC assay determined using CLSI guidelines is 2-fold. *MICs for compounds FOB and 16-Fe 

































































































Figure 2.12. S. aureus ATCC 11632 growth promotion by FOB, Dan-Fe, 5-Fe, and 16-Fe 
supplemented at 1.28 mM under Fe-limiting conditions (TMS minimal media treated with 
200 M 2,2’-dipyridyl). 


























Figure 2.13. S. aureus ATCC 11632 growth curves in iron restrictive TMS minimal media (pH 
7.4) at 37 C with siderophore supplementation. Error bars represent standard deviations for at 
least three independent trials. 

































































































































Figure 2.14. Electrostatic surface models of HtsA (PDB 3li2), SirA (PDB 3mwf), and FhuD2 
(PDB 4fil) bound to ferric complexes of staphyloferrin A (net negative charge), 
staphyloferrin B (net negative charge), and FOB (net positive charge), respectively. 
Positively charged protein surfaces are shown in blue, negative charged protein surfaces are 
shown in red, and charge neutral protein surfaces are shown in light grey.  
Table 2.5. Strains and plasmids used in this work. 
 
Strain Plasmid Inducible Gene/Marker Origin/Reference 
Staphylococcus aureus 
SG511 




None Wild Type ATCC 
E. coli TOP10 None Cloning strain Agilent 
E. coli BL21 (DE3) None Protein expression strain Agilent 
E. coli Top10 pET28a FhuD2 This work 



























































(1)  𝐾 =  [ ]
[ ][ ]
                               for the following equilibrium;  [Fe3+] + [L] ⇌ [FeL] 
(2) 𝐾 =  [ ]
[ ] [ ]
       for the following equilibrium; [Fe3+] + [EDTA] ⇌ [FeEDTA]  
(3) 𝐾 =           for the following equilibrium; [FeEDTA] + [L] ⇌ [FeL] + [EDTA] 




(5) ∆  =    




(7) [𝐹𝑒𝐿] =   
(8) [𝐸𝐷𝑇𝐴] = [𝐸𝐷𝑇𝐴] − ∆             where  [EDTA]T = total EDTA added 
(9)   [𝐹𝑒𝐸𝐷𝑇𝐴] =  ∆ 
(10)       [𝐿] =  ∆ 




Apparent siderophore Fe(III) affinity values (KFe) were determined using a well-established 
competition experiment with EDTA using optical absorbance spectroscopy2. Equations 1–11 and 
equilibria reactions were used to calculate KFe. Equations 1–11 show the equilibria for a general 
ligand (L), which in our case is the siderophore forming a 1:1 complex with Fe(III). We assumed 
there is no free iron in solution. We assumed that all absorbance at 430 nm was due to the presence 
of siderophore-Fe(III) complex and that a loss in absorbance at 430 nm is due to transfer of Fe(III) 
to EDTA. By starting with recrystallized highly pure siderophore-Fe(III) complex we initiated 
ligand exchange by addition of 1.2 equivalents of EDTA, as described in the materials and methods 
section of the main text. By monitoring the absorbance at 430 nm (AbsFeL) we calculated apparent 





Figure 2.15a. Fluorescence quenching curves for titration of N-His6-FhuD2 with siderophores. 
Error bars represent standard deviations for at least three independent trials. 


































































































































Figure 2.15b. Fluorescence quenching curves for titration of N-His6-FhuD2 with siderophores. 
Error bars represent standard deviations for at least three independent trials. 




















































































































































Figure 2.15c. Fluorescence quenching curves for titration of N-His6-FhuD2 with siderophores. 
Error bars represent standard deviations for at least three independent trials. 






















































































































































Figure 2.16. S. aureus ATCC 11632 growth curves in iron restrictive TMS minimal media (pH 
7.4) at 37 C with siderophore supplementation. Error bars represent standard deviations for at 
least three independent trials. 
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 This chapter was adapted with permission from an article of the same title to be 
submitted for publication by Nathaniel P. Endicott, Gerry-Sann Rivera and Timothy A. 
Wencewicz. 
3.2 Abstract  
Iron transport in microbes has been the focus of intense study for decades. Tremendous 
insight has been gained on the regulation, structure, and function of microbial iron transport 
systems, but we still lack a clear mechanistic understanding of the fundamental chemical steps that 
take place during the passage of extracellular iron through the microbial cell envelope. 
Siderophore-mediated iron acquisition has been particularly well studied in microbes and much is 
known about how these small molecules are biosynthesized and excreted to scavenge iron(III) 
from biological sources through formation of high affinity complexes that are imported via 
dedicated membrane transport pathways. Two siderophore-dependent membrane transport 
paradigms for iron have been proposed in bacteria; namely, the “iron shuttle” and “siderophore 
displacement” paradigms. We have developed a kinetic fluorescence quenching assay using a 
fluorescent siderophore probe molecule, DFO-NBD, and a siderophore binding assay using resin-
immobilized siderophore-binding protein, FhuD2, to test the “iron shuttle” and “siderophore 
displacement” paradigms, respectively, at play for trihydroxamate ferrioxamine siderophores 
utilized by the human pathogen Staphylococcus aureus. We have shown that both membrane 
transport paradigms are operational and provide a refined mechanism for FhuD2-catalyzed iron 
exchange whereby FhuD2 transfers its conformational flexibility to displace hydroxamate 
coordinate bonds from the iron(III) metal center using highly conserved Trp197 and Arg199 
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residues that accelerate ligand exchange through hydrogen bonding interactions with hydroxamate 
oxygen atoms. Our study revealed that the predominating transport mechanism depends on 
concentration, siderophore type (linear or macrocyclic), and the biological source of the iron. 
Linear holo-siderophores readily undergo iron exchange as the metal donor, while macrocyclic 
siderophores can only serve as metal acceptors in the apo form due to the rigidified macrocyclic 
framework resisting the conformational plasticity of the siderophore-binding protein required for 
catalyzing iron exchange from the holo-siderophore. We discovered that FhuD2 can recognize 
human transferrin as a substrate and efficiently catalyzes iron exchange from holo-transferrin to 
apo-siderophores revealing a new paradigm for FhuD2-mediated iron acquisition during S. aureus 
infection that sheds new light on the value of surface exposed FhuD2 lipoprotein as a virulence 
factor and viable vaccine target. We hope that our updated mechanistic model of siderophore-
mediated iron acquisition will serve as a useful guide for studying metal trafficking in cells and 
designing next generation siderophore-based therapeutics to combat infectious disease. 
3.3 Introduction 
The spread of antimicrobial resistance is rapidly accelerating and poses a monstrous threat 
to society if left unchecked.1 Overall overuse of antibiotics, incorrect prescriptions, and 
agricultural demand have all contributed to this problem.2-5 The pharmaceutical industry has 
performed poorly in developing new antibiotics. Regulatory barriers and economics are two 
relevant factors, as the economic cost to develop new antibiotics is vastly greater than other kinds 
of diseases.4 Even if new antibiotics are successfully developed, quick spreading of resistance 
often renders new drugs ineffective. The net result of these effects is that very few antibiotics have 
reached phase 2 development in recent years, particularly ones that combat the ESKAPE 
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pathogens.6 The ESKAPE pathogens are a group of bacteria especially notorious for their ability 
to evade traditional antibiotic techniques. Many of these bacteria have developed extensive drug 
resistance, such as multidrug resistant multidrug resistant Pseudomonas aeruginosa and 
methicillin-resistant Staphylococcus aureus (MRSA).1 MRSA in particular is resistant to beta-
lactam antibiotics and is responsible for some of the biggest death toles in the bacterial pathogen 
landscape, being the infection which has caused the most death annually in the U.S.7 Rates of death 
in community settings, especially countries with poor hygiene practices, is projected to continue 
to rise.8 It is therefore imperative to develop a more complete understanding of bacterial virulence 
pathways in order to more intelligently tailor the future generation of antibiotic compounds. 
S. aureus possesses several key virulence factors which aid its ability to thrive in an 
infection setting. These virulence factors are regulated by multiple environmental cues, such as 
temperature, pH, and nutrient availability.9 Regulatory loci are key in the controlling of these 
virulence factors, and the ferric uptake regulators (Fur) are highly involved in the acquisition of 
iron.10 Iron is important for the survival of almost every organism on earth due to its key role in 
processes such as nitrogen fixation, DNA replication, amino acid biosynthesis, oxygen binding 
and catalysis.11 In Its ferric Fe(III) form bacteria need much higher concentrations of iron (10-6 M) 
than is available in an infection setting (10-24).12 Like other bacteria, S. aureus exhibits noticeable 
growth inhibition if iron uptake is blocked.13 The primary way S. aureus addresses the problem of 
iron acquisition is through the use of siderophores, small secondary metabolites which chelate iron 
at high affinity.14-16 Siderophores are biosynthesized intracellularly before excreted to gather iron 
in the extracellular environment, where they return through the cell membrane through ABC 
transporters anchored to the cell membrane in Gram positive bacteria.17 Fur in S. aureus directly 
regulates its siderophore system.18 S. aureus primarily produces two siderophores, staphyloferrin 
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A and B.19 It possesses two unique ABC transporters for Staphyloferrin A and B, HtsABC and 
SirABC, respectively.20,21  
One noteworthy phenomenon in bacteria is the acquisition of siderophores produced by 
other bacteria, called xenosiderophores, as a method of reducing metabolic burden.22 S. aureus is 
no exception to this, and has shown the ability to uptake ferrioxamine xenosiderophores through 
its FhuCBG system.23 Desferrioxamine B (DFOB) is a trihydroxamate siderophore most notable 
for its role as a first line choice in treating iron overload disease. DFOB also has shown promise 
in the areas of infection imaging, drug delivery, burn recovery, wound healing, and as therapy for 
cancer, Parkinson’s, Alzheimer’s and COPD.24-29 The growing threat of antimicrobial resistance 
and use of DFOB makes understanding the iron uptake pathway in FhuD2 vitally important to 
allow for rational design of siderophore therapeutics. 
Long recognized for their role in the uptake of iron-bound siderophores, high iron affinity 
virulence factors which allow pathogenic bacteria to combat nutritional immunity in the host, we 
propose the siderophore-binding protein component of the ABC transporter system (SBP) serves 
an additional purpose as an enzyme catalyzing the nonreductive removal of iron from human 
defense proteins such as transferrin (Figure 3.1). In this work we show apo-siderophores pre-
bound to the SBP serve as cofactors in this iron acquisition process. Traditional dogma for 
siderophore-mediated iron acquisition involves siderophore biosynthesis within the cell followed 
by efflux into the extracellular environment.30-35 Iron-bound siderophores then return to the cell 
where SBPs facilitate cellular re-entry before the iron is released for use in the cell. This 
siderophore system has been considered to function separately from the pathogenic strategy of 
directly binding host iron transporters, as seen in bacterial heme-transport proteins. These methods 
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of iron acquisition are both genetically linked to Fur proteins and must no longer be considered 
independent of each other. 
The capability of non-reductive iron shuttling between siderophores has been implicated  
in studies of YxeB, a siderophore binding protein (SBP) from Bacillus cereus that is homologous 
to FhuD2, by Raymond and coworkers.30 In this shuttle mechanism, an approaching holo-
siderophore to the SBP transfers its iron to an apo-siderophore already bound to the protein. The 
siderophore that has newly received the iron then enters the cell. In an alternative mechanism, the 
incoming holo-siderophore could displace the apo-siderophore on the active site of the protein. 
We utilized a siderophore-fluorescent probe previously designed for use in observing iron uptake 
in plants, 7-nitrobenz-2 Oxa-1,3-diazole-desferrioxamine (DFONBD) as a turn-off probe when 
bound to iron to examine the role of shuttling vs. displacement in S. aureus. A resin-immobilized 
FhuD2 assay was used to qualitatively analyze displacement of multiple siderophores at the SBP 
binding pocket. 
Kinetic rates of iron exchange between DFONBD and a select panel iron-bound 
siderophores were measured by fluorescence quenching both in the presence and absence of 
FhuD2. We found that FhuD2 catalyzed the exchange of iron and lowered apparent iron affinity 
for linear siderophores. These effects were not observed in equivalent cyclic siderophores. To 
examine the biological implications of iron shuttling transferrin was introduced as an iron source. 
Transferrin is one of the most relevant iron transporters in humans and plays a vital role in iron 
sequestration from invading pathogens.  DFOB by itself is unable to access transferrin-bound iron.  
Fluorescence quenching revealed DFONBD poorly acquires iron from holo-transferrin, but rapidly 
does so when FhuD2 is present. LC-MS experiments provided addition evidence that FhuD2 
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facilitates iron removal from transferrin with apo-siderophores (Figure 3.1). A series of active site 
mutants were tested for their ability to catalyze iron exchange and it was found that These findings 
give new meaning to the shuttle mechanism and provide an updated understanding of the 
siderophore paradigm in pathogenic bacteria.  
The exchange of iron between biological sources and high-affinity siderophores is 
thermodynamically favorable, but exceedingly slow kinetically. We present a revised model for 
this iron exchange where the extracellular siderophore-binding proteins play an active role in 
catalyzing this process to provide a meaningful kinetic advantage for iron acquisition in 
siderophore-utilizing bacteria. In our model, the siderophore-binding proteins are not innocent 
bystanders waiting for the diffusion-controlled chance opportunity to snatch a specific holo-
siderophore from the environment, but instead serve as broad catalyst for iron exchange between 
iron-sequestering host proteins and apo-siderophore cofactors localized at the cell surface in the 
binding calyx of surface-displayed siderophore-binding proteins such as FhuD2 in S. aureus and 
YxeB in B. cereus. 
3.4 Results and Discussion 
Development of a Kinetic Fluorescence Quenching Assay for Iron Exchange Between 
Siderophores. 
DFONBD is a turn off fluorescence probe which loses its diagnostic fluorescence emission 
peak at ~550 nm when bound to iron. Monitoring of maximum fluorescence over time represents 
DFO-NBD being converted to FONBD as fluorescence decreases. The viability of the fluorescence 
quenching assay was tested by titrating FeCl3 as an iron source, and the corresponding fluorescence 
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quenching confirmed literature results when different concentrations of FeCl3 were allowed to 
equilibrate with DFONBD for 1 h. Each individual experimental condition can be analyzed over 
time in a fluorescence decay plot normalized to the maximum fluorescence of DFO-NBD at 0 min. 
As an iron source FeCl3 was replaced by iron-bound siderophores, revealing a stronger preference 
for iron exchange between linear siderophores. Cyclic siderophores exhibited minimal iron 
exchange with DFO-NBD. LC-MS experiments verify a direct connection between decreased 
fluorescence and exchange of iron between DFO-NBD and an iron source over time (Figure 3.2). 
Competitive Displacement for Many Siderophores Occurs in the SBP Active Site 
While the shuttle mechanism could be tested using the fluorescent DFO-NBD probe, the 
displacement mechanism was tested using a resin-immobilized FhuD2 system previously 
developed for purifying siderophore natural produces from complex Streptomyces fermentations.36 
In this assay, purified N-His6 FhuD2 is bound to a Ni-NTA resin and is first loaded with a single 
siderophore or a mixture of siderophores depending on the nature of the desired competition study. 
The column is washed with buffer until the siderophores added are longer detected by LC-MS. 
Afterward, a separate siderophore is added to the column in an elution step, which displaces the 
initially bound siderophore that is detectable LC-MS in the elution buffer, confirming 
displacement of siderophores has occurred from FhuD2(Figure 3.3). All of the siderophores used 
in this study were confirmed to competitively displace each other on resin-immobilized FhuD2 
and YxeB, including the DFO-NBD fluorescent probe, linear ferrioxamine siderophores, and 




FhuD2 Catalyzes Iron Exchange Between Linear Siderophores. 
The fluorescence quenching assay for measuring iron exchange between an iron-bound 
siderophores was repeated in the presence of FhuD2. Low concentrations of FhuD2 was pre-
complexed with the iron-bound siderophore before mixing with DFO-NBD. A big difference in 
iron exchange was observed when linear iron-bound siderophores first bound to FhuD2 were 
mixed with DFO-NBD. This large drop in fluorescence quenching caused by FhuD2 was not 
observed for cyclic siderophores serving as the ferric iron source. We found that macrocyclic 
siderophores can only serve as metal acceptors, not donors during redox neutral SBP-catalyzed 
iron exchange. (Figure 3.4). LC-MS was used to confirm iron exchange was occurring in the 
fluorescence quenching assay conditions. 
Iron Exchange from holo-Transferrin. 
Fluorescence quenching of DFO-NBD in the presence of holo-transferrin as an iron source 
was tested. Very little iron exchange occurred without FhuD2 present in the reaction holo-
transferrin appeared to bind FhuD2 at nanomolar affinity when using an intrinsic tryptophan 
fluorescence quenching experiment. Using holo-transferrin as the source of ferric iron in the 
FhuD2-catalyzed iron exchange experiment with DFONBD revealed a profound degree of 
fluorescence quenching indicating a large degree of iron exchange from transferrin to DFONBD. 
This was confirmed by LCMS using DFOB and DFOE as siderophore cofactors for FhuD2. We 
evaluated the effect of time and transferrin concentration on the iron exchange using steady-state 
Michaelis-Menten studies. Human transferrin proved to be an efficient substrate for FhuD2 and 
apparent Km values correlated with the nanomolar binding affinities measured in the intrinsic Trp 
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fluorescence quenching studies, which further supports a catalytically productive interaction 
between FhuD2 bound to DFONBD and iron donating substrate transferrin.  
Iron Exchange from holo-Transferrin from FhuD2 active site mutants 
A series of active site mutants of FhuD2 was analyzed for their ability to catalyze iron 
exchange between a siderophore and holo-transferrin in the DFO-NBD fluorescence quenching 
assays. The FhuD2 mutants were also evaluated in the immobilized FhuD2 siderophore 
displacement assay. Collectively these studies revealed active site residues important for 
siderophore binding and catalysis of iron exchange. A total of eight active site mutants were 
prepared (Y256F, Y106F, R175A, W255A, Y254F, Y167F, Y169F, W173A) guided by the crystal 
structure of FhuD2 bound to FOB (PDB 4FIL) (Table 3.1, Figure 3.5). We identified several 
active site residues that impact substrate binding and iron exchange. R175 and W173 are the only 
two residues that make direct contact with the bound siderophore cofactor. Mutation of these 
residues to Ala resulting in at least an 8-fold drop in catalytic efficiency. For the R175A mutant, 
this drop in catalytic efficiency was attributed to decreased affinity for substrate. However, for the 
W173A mutant, the drop in catalytic efficiency was attributed to a significant drop in kcat 
suggesting a role for W173A in the iron exchange mechanism (see below). Several of the Tyr 
mutants exhibited enhanced substrate binding affinity, but a loss in catalytic efficiency associated 
with impaired iron exchange. Specifically, Tyr167 and Tyr169 showed a significant drop in 
catalytic efficiency compared to WT FhuD2 (~4-fold), which led us to propose a key role in iron 
exchange via ligand displacement and metal chelation. Displacement studies using immobilized 
FhuD2 mutants corroborated the binding data from the steady state Michaelis-Menten studies and 
supported impaired siderophore-binding capability of some mutants. 
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Mechanism for FhuD2-Catalyzed Iron Exchange. 
We propose a mechanistic solution to FhuD2 catalysis of linear iron exchange based on 
dynamic motion of FhuD2. The binding pocket of FhuD2 does not come in contact with iron, so 
natural dynamics function to peel linear siderophores away from the metal utilizing certain key 
residues in the active site (Figure 3.6). Comparison of the “closed” (PDB 4FIL) and “open” (PDB 
4FNA) forms of FhuD2 using the PyMOL Morph function revealed dynamic motions of several 
key active site residues indicated in substrate binding and catalysis by our functional studies 
(Figure 3.5). We propose a mechanism for iron exchange where the bound siderophore acts as a 
cofactor and acceptor of ferric iron from a variety of biological sources including transferrin 
(Figure 3.6). A linear siderophore cofactor such as DFOB can move with the dynamic motions of 
FhuD2 due to the inherent conformational flexibility. Macrocyclic siderophores are more rigid and 
thus resist conformational dynamics of the SBP. We reached this conclusion by measuring 
apparent iron affinities of stoichiometric ferric siderophore-FhuD2 complexes using an EDTA 
competition experiment. We found that complexation to FhuD2 lowered the apparent KFe values 
for linear, but not macrocyclic siderophores, suggesting that FhuD2 does promote a more 
kinetically and thermodynamically more labile ferric iron metal center consistent with the 
proposed role as an iron exchange catalyst. 
As outlined in Figure 3.6, we propose an initial binding interaction between an iron-free 
siderophore-FhuD2 complex and ferric transferrin. For related substrate binding proteins such as 
maltose binding protein, the effect of molecular crowding by hydrophobic proteins has been 
demonstrated to promote transition from an “open” to “closed” conformation.37 The transition 
from “open” to “closed” promotes movement of key residues (Figure 3.5), including Tyr167 and 
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Tyr169 that we propose to displace mobile ligands from the transferrin ferric iron center to form 
an intermediate FhuD2-transferrin co-complex of ferric iron. The nearby hydroxamate ligands of 
the bound siderophore cofactor are now positioned to displace the remaining transferrin ligands 
giving apo-transferrin and a bound ferric siderophore iron complex in the “closed” FhuD2 active 
site. Dissociation of transferrin enables the ferric SBP to interact with this FhuABC permease to 
facilitate import of the ferric siderophore iron complex. 
DFO attenuates fluorescence quenching of DFO-NBD. 
We obtained an additional supportive piece of experimental evidence to demonstrate that 
the iron exchange process observed via LCMS and fluorescence quenching was indeed 
siderophore and FhuD2-dependent. In the DFO-NBD iron exchange assay, we included increasing 
concentrations of DFO as a competing iron acceptor siderophore cofactor (Figure 3.8). The 
addition of increasing amounts of DFO led to a reduced amount of fluorescence quenching, 
indicating DFO-NBD fluorescence quenching was a direct result of acquiring iron from a specific 
iron source. DFO and DFO-NBD possess similar iron binding affinities and should therefore 
function similarly as substrates for iron from a source such as holo-transferrin. This result suggests 
that developing structurally optimized ferrioxamine siderophores with enhanced binding and 
improved iron affinity might enable inhibition of the iron exchange step in siderophore utilization 
by the Fhu system in S. aureus as a novel antivirulence therapeutic strategy. 
3.5 Further Discussions and Conclusions 
The proposed mechanism for SBP iron acquisition through apo-siderophores has several 
biological advantages. Notably, the concentration gradient of iron-free siderophores is greatest 
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immediately near the cell membrane, resulting in promiscuous binders such as FhuD2 being 
mostly in the state of being bound to apo-siderophores. Binding apo-siderophores to SBPs on the 
cell surface additionally prevents loss of the cell’s own siderophores through surface localization. 
Relying on the return of produced siderophores in an environment with many competing cells 
would likely be energetically unfavorable and fights the principles of passive diffusion. Utilizing 
a cell’s own siderophores as an iron transport cofactor while minimizing the risk of another 
bacterial cell stealing siderophores provides bacteria with a distinct competitive advantage in an 
infection environment. A further advantage is the utilization of macrocyclic siderophores to as iron 
receivers when bound to the protein, perhaps more reliably delivering iron into the cell since 
conformational dynamics result in loss of iron from a macrocyclic siderophore being less likely 
when bound to a SBP such as FhuD2 (Figure 3.8). 
The fluorescence quenching assay with FhuD2 does present complications to consider. All 
that is being measured in the fluorescence decay assay is the conversion of DFO-NBD to FO-
NBD. After initial catalysis of this conversion by FhuD2, multiple competing equilibria results in 
the rate of fluorescence decay becoming similar to the non-enzymatic rate after several minutes. 
As more FO-NBD forms in solution, it becomes more likely to self-exchange with other DFO-
NBD molecules, resulting in a net zero in fluorescence quenching. Additionally, FO-NBD 
becomes more likely to exchange back to DFO-NBD as time increases, resulting in a fluorescence 
recovery affect. The order of addition of FhuD2 was explored. FhuD2 was found to increase 
intrinsic fluorescence of DFO-NBD. FhuD2 pre-bound to DFO-NBD drowned out the initial 
signal, giving the illusion of no iron exchange. Therefore, FhuD2 pre-bound to the iron source was 
the standard order of addition in all assays. 
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The quantitative rates of displacement were not measured but showed noticeable difference 
across many of the active site mutants tested. This points to the idea that the rate of displacement 
vs. shuttle could be governed by affinity for the active site. Iron sources with similar or much 
higher affinity for the active site than the bound apo-siderophore would be more likely to undergo 
displacement than shuttle. Likewise, iron sources with much lower affinity for the binding site or 
sources too large to access the site at all, as is the case of holo-transferrin, would be pushed toward 
the shuttle mechanism. Additional studies with mutants and developing a better structural 
understanding of what constitutes high affinity binding would be an intriguing avenue to pursue 
going forward. A siderophore with too high of binding to the SBP could actually show growth 
inhibition for the system if the siderophore sticks to the SBP and is not able to be pushed into the 
cell or displaced off the protein.  
Antimicrobial resistance is one of the most pressing problems in modern medicine. 
Bettering our understanding of bacterial iron acquisition is one step in combating antimicrobial 
resistance. FhuD2 catalyzed iron acquisition sheds light on why FhuD2 has shown promise as a 
vaccination target even though it was previously understood to play a secondary role in iron-bound 
siderophore uptake.  The extent to which this FhuD2-mediated iron acquisition mechanism occurs 
in other bacterial systems could be explored to discover new SBP vaccination targets. S. aureus 
has a myriad of ways to sequester iron from its environment. Staphyloferrin A has been linked to 
the ability to pull iron directly from human transferrin. Thus, the FhuD2 mechanism for iron 
acquisition from transferrin appears somewhat redundant on the surface. This indicates the 




3.6 Materials and Methods 
Synthesis of DFO-NBD. 
DFO-NBD was synthesized as described previously in Chapter 2. 656 mg of 
desferrioxamine B mesylate was dissolved in 10 mL methanol. 200 mg of NBD-Cl was dissolved 
in 7.5 mL methanol. Both these solutions were added to 20 mL of 0.1 N NaHCO3 and the entire 
mixture was heated in an oil bath for 1 h. The mixture was concentrated under reduced pressure 
and purified via prep HPLC. FO-NBD was formed by adding 1.1 equivalents of Fe(acac)3 to DFO-
NBD and letting mix for 1 hour. 
KFe determination. 
Apparent iron affinity of siderophores and siderophore-FhuD2 complexes were measured 
as described previously. 0.12 mM EDTA was added to 0.1 mM siderophore-Fe(III) in HEPES (10 
mM HEPES, 100 mM KCl 600 mM NaCl, pH 7.4) to give a final volume of 1 mL. For the FhuD2 
assay 0.1 mM siderophore-Fe(III) was mixed with 0.1 mM FhuD2 in HEPES for 15 min before 
0.12 mM EDTA was added to give a final volume of 1 mL. The mixture was continuously analyzed 
for 90 min at 1 scan/s (480 nm for DFONBD, 430 nm for other siderophores) by optical absorbance 
spectroscopy using a methacrylate cuvette. The analyzed absorbance correlating to a given 
siderophore-Fe(III) complex decreased by pseudo first-order kinetics. The minimum absorbance 
as a thermodynamic endpoint was used to calculate apparent KFe using an extinction coefficient 





FhuD2 determination of Kd. 
FhuD2 was prepared as described previously. N-His6-FhuD2 was thawed on ice from a 
−80 °C freezer stock. 5.4 μM stock solutions were made in TBS buffer (25 mM TrisHCl, 0.2 g/L 
KCl, 8 g/L NaCl, pH 7.4) and diluted 1:50 to obtain ∼100 nM solutions of N-His6-FhuD2 for the 
following assay. 4 uM solutions of FOE or transferrin were prepared in H2O. Increasing 
concentrations of FOE (final concentration range: 0, 26.7, 53.2, 79.5, 105.6, 171, 299, 422, and 
881 nM) were added to a solution of N-His6-FhuD2 at 100 nM final concentration in TBS buffer 
at a final volume of 300 uL. A PerkinElmer LS 55 Luminescence Spectrometer was used to analyze 
maximum fluorescence at ~340 nm over time at emission range 300-400 nm and 280 nm excitation 
and a scan speed of 400 nm/min. Emission slits were set to 10 nm and a HellmaAnalytics High 
Precision Cell cuvette made of Quartz SUPRASIL was used with a light path of 10 × 2 mm. 
Fluorescence intensity versus concentration of FOE was plotted, and Graphpad Prism v7.0b was 
used to calculate apparent Kd using a one site binding model by nonlinear regression. The above 
was repeated for holo-transferrin in place of FOE. All experiments were performed at least in 
duplicate. 
Intrinsic Trp fluorescence quenching. 
0.5 uM FeCl3 was added to 2 uM DFO-NBD in HEPES at a final volume of 200 uL. A 
PerkinElmer LS 55 Luminescence Spectrometer analyzed maximum fluorescence at ~540 nm over 
time at emission range 500-600 nm and 475 nm excitation with a scan speed of 100 nm/min. 
Emission slits were set to 10 nm and a HellmaAnalytics High Precision Cell cuvette made of 
Quartz SUPRASIL with a light path of 10 × 2 mm was used. Scans were taken periodically out to 
3 h. Each point of maximum fluorescence at a given time was normalized relative to the maximum 
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fluorescence at 0 min. The maximum fluorescence at 0 min represents 100% DFONBD. These 
experiments were repeated at 1, 1.5, 2, 4, and 8 uM FeCl3. The concentration of FeCl3 vs. relative 
fluorescence at 60 min for each different concentration of FeCl3 was plotted using Graphpad Prism 
v7.0b. All experiments were performed at least in duplicate. 
Fluorescence-based kinetic assay for iron exchange. 
A set concentration (usually 2 uM) of DFO-NBD was mixed with 0.5 uM of an iron source 
(iron-bound siderophore or holo-Tf) at a final volume of 200 uL and maximum fluorescence at 
~540 nm was monitored over time, once per minute for the first 15 min, then at 30 min and finally 
at 60 min. The same fluorimeter setup as the FeCl3 experiment was used. Relative fluorescence 
intensity to the maximum fluorescence intensity at 0 min was plotted against time using Graphpad 
Prism v7.0b. These experiments were repeated at 1, 1.5, 2, and 4 uM of an iron source. The above 
was then repeated at a constant concentration of the iron source and variable DFO-NBD. Finally, 
every reaction condition was repeated in the presence of 100 nm FhuD2 which was first allowed 
to mix with the iron source for 15 min before DFO-NBD was added. All experiments were 
completed at least in duplicate. 
Siderophore displacement from immobilized FhuD2. 
This procedure is adapted from a procedure reported in Rivera, G. S. M.; Beamish, C. R.; 
Wencewicz, T. A. ACS Infectious Diseases 2018, 4, 845-859. A fritted glass column was loaded 
with fresh Ni-NTA agarose resin in 1:1 EtOH:H2O to give a working resin volume of 2.3 cm x 1 
cm. The resin was washed with H2O and equilibrated with SBP buffer (50 mM K2HPO4, 150 mM 
NaCl, 1 mM DTT, pH 8) at 4 °C. N-His6-FhuD2 was thawed from a frozen stock (100 μL of 3.8 
mM in SBP buffer; this is enough protein to fully saturate the Ni-NTA agarose resin), diluted to 3 
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mL final volume with SBP buffer, and added to the Ni-NTA agarose resin. After rocking at 4 °C 
for 30 min excess SBP buffer was eluted and the column was washed with SBP buffer until no N-
His6-FhuD2 was detected by SDS-PAGE analysis. The N-His6-FhuD2-saturated Ni-NTA agarose 
resin is referred to as SBP-resin. Five siderophores (FO-B, FO-NBD, FO-E, and Dan) were used 
in pairs as the siderophore of interest (S1) or sacrificial siderophore (S2). Siderophore S1 is first 
loaded to the SBP-resin by addition of 5 mL of a 0.02 mg/mL solution of S1 in SBP buffer followed 
by 20 min of rocking at 4 °C. Excess SBP buffer is eluted and the SBP resin is washed five times 
with 15 mL of SBP buffer until LC-MS analysis shows no detectable ions for siderophore S1. Next, 
5 mL of a 0.02 mg/mL solution siderophore S2 in SBP buffer is added and the SBP resin is rocked 
at 4 °C for 20 min. The column eluent is analyzed by LC-MS for the presence of siderophore S1 
ions to confirm displacement from the SBP resin by competitive binding of excess siderophore S2. 
The SBP resin can now be used in a second cycle using the now resin bound siderophore S2 as the 
siderophore of interest S1. For LC-MS analysis of samples a gradient was formed from 5% B to 
95% B over 20 min, followed by a 3 min hold at 100% B, and re-equilibration to 5% B over 2 min. 
Caution: using DTT in SBP buffer can lead to reduced Ni-NTA resin as indicated by a blue to 
orange color change during the procedure. BME can be used as an alternative to DTT to prevent 
this from taking place. Each experiment was performed in duplicate as independent trials. 
Siderophore mix displacement with SBP-resin. 
This procedure is adapted from a procedure reported in Rivera, G. S. M.; Beamish, C. R.; 
Wencewicz, T. A. ACS Infectious Diseases 2018, 4, 845-859. A fritted glass column was loaded 
with fresh Ni-NTA agarose resin in 1:1 EtOH:H2O to give a working resin volume of 2.3 cm x 1 
cm. The resin was washed with H2O and equilibrated with SBP buffer (50 mM K2HPO4, 150 mM 
NaCl, 1 mM DTT, pH 8) at 4 °C. N-His6-FhuD2 was thawed from a frozen stock (100 μL of 3.8 
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mM in SBP buffer; this is enough protein to fully saturate the Ni-NTA agarose resin), diluted to 3 
mL final volume with SBP buffer, and added to the Ni-NTA agarose resin. After rocking at 4 °C 
for 30 min excess SBP buffer was eluted and the column was washed with SBP buffer until no N-
His6-FhuD2 was detected by SDS-PAGE analysis. The N-His6-FhuD2-saturated Ni-NTA agarose 
resin is referred to as SBP-resin. A mixture of five siderophores (FO-B, FO-NBD, FO-E, and 
Dan) were used as the siderophores of interest, with the sixth siderophore (SFO) as the sacrificial 
siderophore. The mixture of five siderophores is first loaded to the SBP-resin by addition of 5 mL 
of a 0.005 mg/mL solution of each siderophore in SBP buffer followed by 20 min of rocking at 4 
°C. Excess SBP buffer is eluted and the SBP resin is washed five times with 15 mL of SBP buffer 
until LC-MS analysis shows no detectable ions for siderophore S1. Next, 5 mL of a 0.02 mg/mL 
solution SFO in SBP buffer is added and the SBP resin is rocked at 4 °C for 20 min. The column 
eluent is analyzed by LC-MS for the presence of each siderophore in the mixture (FO-B, FO-
NBD, FO-E, and Dan) ions to confirm displacement from the SBP resin by competitive binding 
of excess siderophore SFO. For LC-MS analysis of samples a gradient was formed from 5% B to 
95% B over 20 min, followed by a 3 min hold at 100% B, and re-equilibration to 5% B over 2 min. 
Caution: using DTT in SBP buffer can lead to reduced Ni-NTA resin as indicated by a blue to 
orange color change during the procedure. BME can be used as an alternative to DTT to prevent 
this from taking place. Each experiment was performed in duplicate as independent trials. 
LC-MS confirmation of iron exchange. 
50 uM of an iron source (iron-bound siderophore or holo-Tf) was mixed with 50 uM of 
iron-free siderophore in HEPES at a final volume of 200 uL and analyzed by relative % formation 
of the new iron-bound siderophore over time by LC-MS. An Agilent 6130 quadrupole with G1313 
autosampler, 1200 series solvent module, and G1315 diode array detector was used in LC-MS 
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analysis. The experiment was repeated except in the presence of 10 uM FhuD2 that is allowed to 
equilibrate with the iron source for 15 min before the iron-free siderophore is added. All 
experiments were performed at least in duplicate. 
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3.8 Tables and Figures 
 
 
Figure 3.1. Schematic representation of the (a) “iron shuttle” and (b) “siderophore shuttle” 
membrane transport paradigms proposed by Raymond. In this work, we show that SBPs catalyze 





Figure 3.2. Siderophore-binding proteins (SBPs) catalyze the exchange of ferric iron from human 
transferrin to a siderophore cofactor. (a) General reaction scheme for the use of desferrioxamine-
2-(4-nitro-2,1,3-benzoxadiazol-7-yl) conjugate (DFO-NBD) as a “turn off” fluorescent iron 
sensing probe that quenches upon chelation of iron(III). (b) Graph depicting relative fluorescence 
emission quenching of 2 μM DFO-NBD (excitation = 475 nm; emission = 565 nm) in the time domain 
using no SBP, 100 nM FhuD2, or 100 nM YxeB and 4 μM ferric human transferrin as the iron 
source. (c) Graph depicting the percentage change in the relative fluorescence emission of DFO-
NBD (excitation = 475 nm; emission = 565 nm) after 15 minutes of incubation with 100 nM SBP 
(FhuD2 or YxeB) and 4 μM ferric iron source (FOB, FOE, or transferrin) relative to a control 
reaction with no added SBP. (d) Michaelis-Menten plot with apparent steady-state kinetic 
parameters for the exchange of ferric iron from variable transferrin to constant DFO-NBD (2 μM) 
catalyzed by 100 nM SBP (FhuD2 or YxeB). Error bars in all panels represent standard deviations 




Figure 3.3. Ferrioxamine siderophores (FOB, FOE, and FONBD) bind reversibly and 
competitively to resin-immobilized FhuD2 and YxeB Siderophore binding proteins from S. aureus 
and B. subtilis, respectively. N-His6-FhuD2 (a) or N-His6-YxeB (b) was immobilized on Ni-NTA 
resin and loaded with a mixture of siderophores [Fe(Sid1)] (FOB, FOE, and FONBD), washed 
with phosphate buffer, and eluted with [Fe(Sid2)] (SFO). Column elutions were analyzed by LC-
MS for each siderophore component in the load [Fe(Sid1)] (m/z = 614, 654, and 777 for FOB, 
FOE, and FONBD [M+H]+ ions, respectively). Extracted ion chromatograms (EIC) are shown for 




Figure 3.4. Macrocyclic siderophores can accept, but not donate, ferric iron during SBP-catalyzed 
exchanges. (a) Graph depicts the relative fluorescence emission quenching of 2 μM DFO-NBD 
(excitation = 475 nm; emission = 565 nm) after 60 minutes of incubation with 100 nM FhuD2, 2 μM 
ferric transferrin, and variable concentrations of competing DFOB (0–4 μM). (b) Graph depicts 
the log of extracted ion counts (EICs) for [Fe(Sid)] complexes, FOB or FOE, after treatment of 50 
μM DFOB or FOE, respectively, with 50 μM ferric transferrin without or with 10 μM SBP (FhuD2 
or YxeB). All EICs were normalized to a quinoline internal standard. The graphs in panels (c) and 
(d) depict the relative percentage of (c) FOB or (d) FOE remaining after treatment with 1.2 
equivalents of EDTA in the presence or absence of stoichiometric FhuD2. Siderophore 
concentrations were determined by optical absorbance at 427 nm. The apparent ferric iron affinity 
(log KFe) was calculated from the decay plots. Error bars in all panels represent standard deviations 
for at least two independent trials. The shaded regions above the curve in panels (c) and (d) 
represent the error bars for every single data point along the continuously recorded data set; ****p 











Figure 3.5. Mutational scanning of FhuD2 reveals active site residues involved in substrate 
binding and catalysis. (a) Active site residues in FhuD2 that were mutated. Color-coding of 
residues matches data sets in all panels. (b) Michaelis-Menten plot for wild-type and mutant 
FhuD2 variants (100 nM) reveals saturation kinetics for ferric transferrin and apparent changes in 
vmax for the exchange of ferric iron to 2 μM DFO-NBD. (c) Relative binding and displacement of 
FOB to wild type and mutant FhuD2 variants. N-His6-FhuD2 variant was immobilized on Ni-NTA 
resin and loaded with FOB, washed with phosphate buffer, and eluted with SFO. Column elutions 
were analyzed by LC-MS for FOB (m/z = 614 for [M+H]+). Extracted ion chromatograms (EIC) 
are shown for FOB and were normalized to a quinoline internal standard. EICs are representative 
for at least two independent trials. (d) Stacked state model of the transition from “open” (dark, 
opaque residues) to “closed” (transparent residues) for FhuD2 highlighting residue dynamics. 
Panels (e) and (f) show surface models for FhuD2 in the (e) “closed” and (f) “open” states revealing 
a cleft from the movement of Y167, Y169, and W173. Images in panels (a), and (d)–(f) were 
generated using PyMOL v2.2 (Schrödinger, Inc.). The stacked state model in panel (d) was 
generated using the morph function in PyMOL. The “closed” and “open” states of FhuD2 were 
generated from PDB entries 4fil and 4fna, respectively. Error bars in panel (b) represent standard 




Figure 3.6. Mechanistic model for iron exchange from an octahedral ferric iron source (transferrin 





Figure 3.7. Model for iron exchange based on dynamic motions of FhuD2 causing disorder of the 
bound siderophore-Fe complex. FhuD2 can adopt “closed” and “open” forms in solution and solid 
state. This model suggests that the dynamic motion of FhuD2 can lower the siderophore iron 
affinity (KFe) of (a) linear siderophores to make iron exchange to a diffuse siderophore both 
kinetically and thermodynamically favorable. (b) EDTA competition assay shows that 
stoichiometric FhuD2 lowers the apparent iron affinity of the linear siderophore FOB. (c) 
Macrocyclic siderophores are more rigid and less responsive to the dynamic motions of FhuD2. 
(d) EDTA competition assays shows that stoichiometric FhuD2 has no effect on the apparent iron 
affinity of the macrocyclic siderophore FOE. (d) Overlay of liganded (blue; PDB 4FIL) and 
unliganded (salmon; PDB 4FNA) FhuD2 in “closed” and “open” conformations, respectively, 
highlighting the spatial orientation of conserved residues E97, W197, R199, and E231. For panels 
(b) and (d) the shaded region above and below the curve represents standard deviation for two 
independent trials. EDTA competition reactions were carried out in HEPES buffer at pH 7 at room 
temperature in the presence (w/) or absence (w/o) of stoichiometric FhuD2 using 1.2 equivalents 
of EDTA with continuous monitoring of optical absorbance at 427 nm, the characteristic 
absorbance for trihydroxamate iron(III) complexes. 
 


















































w/o FhuD2: log KFe = 30.3  0.4
w/ FhuD2 log: KFe = 28.5  0.1
w/o FhuD2: log KFe = 32.4  0.1






Figure 3.8. DFO attenuation of iron exchange from FOB (right) and holo-transferrin (left) to DFO-
NBD. DFO directly competes with DFO-NBD for the iron, thus the fluorescence quenching of 
DFO-NBD is less pronounced at higher concentrations of DFO. 
 








app. Kd (nM) 
transferrin DFOB FOB FOE 
YxeB 40 ± 10a 0.5 ± 0.02 10 ± 3 100 ± 40 30 ± 20 50 ± 30 30 ± 9 
FhuD2 50 ± 10 0.4 ± 0.02 8 ± 0.2 70 ± 30 90 ± 10 30 ± 6 50 ± 6 
Y256F 150 ± 30 0.4 ± 0.01 2 ± 0.5 70 ± 9 80 ± 30 60 ± 10 40 ± 20 
Y106F 80 ± 10 0.3 ± 0.01 4 ± 0.5 100 ± 10 80 ± 20 40 ± 8 80 ± 10 
R175A 220 ± 50 0.3 ± 0.02 1 ± 0.3 110 ± 30 40 ± 9 30 ± 9 50 ± 20 
W255A 350 ± 110 0.3 ± 0.02 0.6 ± 0.2 110 ± 80 60 ± 20 60 ± 50 30 ± 9 
Y254F 40 ± 10 0.2 ± 0.01 6 ± 0.8 90 ± 20 50 ± 10 10 ± 2 20 ± 3 
Y167F 50 ± 20 0.2 ± 0.01 3 ± 1 80 ± 20 60 ± 9 40 ± 6 30 ± 3 
Y169F 50 ± 20 0.1 ± 0.01 2 ± 1 110 ± 20 70 ± 10 40 ± 9 20 ± 2 
W173A 50 ± 10 0.03 ± 0.002 0.9 ±0.1 140 ± 30 100 ± 50 60 ± 8 90 ± 30 
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4.2 Summary of Dissertation 
The structural basis of xenosiderophore utilization in S. aureus facilitated by the surface 
displayed SBP FhuD2, a membrane-anchored lipoprotein, was studied at the level of the substrate 
through a comprehensive look at a panel of DFO analogs and chemical probes. The goal was to 
establish structure-function relationships for the ferrioxamine siderophores with respect to binding 
iron, binding FhuD2, and promoting S. aureus growth under iron-deficient conditions. Using a 
panel of synthetic ferrioxamine analogs, iron affinity and kinetic stability of the siderophore-
iron(III) complexes were determined by an EDTA competition assay. FhuD2 binding was 
measured through intrinsic tryptophan fluorescence quenching experiments. S. aureus growth 
recovery was analyzed with an iron-deficient minimal media in which iron-bound siderophore was 
the only iron source. Competition for cell entry was determined with a siderophore-sideromycin 
competition assay using minimal inhibitory concentration (MIC) as readout. Surprisingly, 
siderophore uptake in S. aureus was determined to be primarily dependent on net siderophore 
charge, regardless of iron affinity, kinetic stability, and FhuD2 binding.  
At this stage it was important to dig deeper into the molecular mechanisms of FhuD2-
mediated siderophore transport in S. aureus. Specifically, distinguishing the shuttle and 
displacement mechanisms proposed originally by Professor Ken Raymond would provide insight 
into how specifically cell entry by the holo-siderophore occurs. The development of a siderophore 
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displacement assay using resin-immobilized FhuD2 and a fluorescence quenching assay for iron 
trafficking using a fluorophore-siderophore conjugate provided the basis for studying shuttle and 
displacement. FhuD2 was found to reversibly siderophores, allowing for dynamic displacement of 
bound siderophores. FhuD2 was also shown to catalyze the exchange of iron between two 
siderophores. The direct role of FhuD2 in virulence led to the pursuit of functional alternatives to 
xenosiderophore iron exchange in a biological setting. Thus, the ability of FhuD2 to exchange the 
iron from human holo-transferrin to a siderophore was explored with the designed fluorescent 
siderophore chemical probe, where FhuD2 rapidly catalyzed iron exchange from holo-transferrin 
to an apo-siderophore at a much higher rate than the siderophore-siderophore exchange. Notably, 
siderophores without FhuD2 were unable to extract iron from holo-transferrin on a meaningful 
time scale. 
FhuD2 appears to be playing an iron trafficking role in S. aureus as an enzyme that 
catalyzes the transfer of iron from human holo-transferrin to a bound siderophore cofactor which 
is subsequently imported into the cytoplasm. The use of the “turn-off” siderophore fluorescent 
probe molecule was validated by LC-MS to detect iron exchange from holo-transferrin to a variety 
of siderophores. The fluorescence assay allowed for kinetic measurements of iron exchange to 
determine if FhuD2 was behaving as a true enzyme. The kinetic effect was dependent on FhuD2 
concentration and fit the Michaelis-Menten model. This validates the emergence of enzyme 
catalysis for iron exchange in a siderophore-binding protein. To probe the molecular mechanism 
for FhuD2-catalyzed iron exchange, the panel of FhuD2 active site mutants was prepared using 
the x-ray crystal structure of FhuD2 bounds to FOB as inspiration. Several residues were identified 
to be critical for iron exchange and siderophore binding which sheds light on the possible 
underlying mechanism from ligand exchange on the metal involving tyrosine residues as iron 
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chelators. Some of the mutants are also compromised for the ability to undergo siderophore 
displacement, which begins to connect the shuttle and displacement steps in the overall membrane 
transport paradigm. Using this knowledge, the same activity was verified in a related SBP from 
Bacillus subtilis, YxeB, to show that catalysis of iron exchange by SBPs is likely widespread in 
Gram-positive bacteria. The newly proposed mechanistic model is a reimagined siderophore 
uptake paradigm in which siderophores function as critical cofactors in the active site of FhuD2 
and other SBPs, allowing these proteins to serve vital and flexible roles in scavenging iron from 
biological sources such as human holo-transferrin using xenosiderophores present in the human 
microbiome (Figure 4.1). 
4.2 Future Directions & Broader Context 
Development of an improved fluorescent probe is one major source of improvement for 
this work. While the simplicity of the chosen probe is a major advantage from an experimental 
standpoint, the capability to only effectively measure one direction of exchange, i.e. the acceptance 
of iron, limits some of the probe’s effective scope. Work was done with measuring loss of iron 
from the probe, but ultimately unsuccessful results were achieved due to the initial moments of 
exchange blending closely with the background signal, causing unacceptable amounts of error 
(likely due to low signal-to-noise ratio) in the vital early kinetic moments of the reaction. An 
alternate probe that might quench fluorescence when loss of iron occurs could be an interesting 
complement to the current system. The binding of FhuD2 to DFO-NBD exposes another potential 
issue with the system. Experimentally the iron source to be acquired by DFO-NBD must start 
bound to the protein, which is not necessarily the direction of the process believed to be dominant 
in a biological setting. Altering the probe to possibly not be affected as much by protein binding 
could be a positive improvement. The concentration gradient of apo-siderophores being effluxed 
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after biosynthesis in the intracellular space dictates surface-bound proteins such as FhuD2 should 
be mostly in the iron free state, due to apo- and holo-siderophores both having similar affinity to 
the binding pocket. Therefore, the most common exchange in nature should be the acceptance of 
iron by an apo-siderophore already about to the SBP, or displacement by an incoming holo-
siderophore. Directly measuring iron acceptance by a probe already protein-bound would be highly 
desirable in the development of future probes.  
Another way to better develop the fluorescent probe would center on a deeper 
understanding of protein binding. While the focus of the current work has only included a 
qualitative analysis of displacement rates and equilibrium constants of binding of siderophores to 
the SBP of interest, an in-depth SAR analysis of the types of residues important in protein binding 
would allow the development of a probe that would either be highly favored to undergo 
displacement or shuttle depending on the affinity difference between it and the other iron source 
of interest. If a probe were designed to have very low affinity for the binding pocket, then it would 
be reasonable to say that the shuttle mechanism would be unfavored if the probe of interest were 
already protein-bound. Likewise, a low affinity probe if starting in the protein-bound state would 
highly favor the displacement mechanism. If the probe were designed to have a high affinity for 
the binding site, then shuttle would be highly favored if the probe started bound to the protein, and 
displacement would be highly favored if the probe started unbound to the protein. One advantage 
of dictating which mechanism is favored would be to more directly measure the shuttle 
mechanism. In the current setup, displacement does play a significant role in our assay, potentially 
causing a large “silent” effect when attempting to directly measure iron exchange. If displacement 
is roughly favored compared to shuttle, then measuring Michaelis-Menten parameters becomes 
much more difficult due to higher error. There would be several ways to design a more tailored 
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fluorescent probe. The panel of analogs from the first paper would be a good starting point in 
combination with the series of active site mutants. A detailed analysis of binding affinity of each 
of the analogs to each of the mutants would in theory provide a good set of rules for important 
residue and functional group interactions are required for higher affinity binding. Crystallography 
on various siderophores bound to multiple active site mutants would be a further guide into the 
development of high or low affinity fluorescent siderophore probes. 
Another aspect in which the fluorescent probe could be improved is in the actual 
fluorescence signal intensity of the compound. The fluorescent signal intensity of the DFO-NBD 
probe is quite low compared to that of intrinsic fluorescence intensity of the SBPs for example. 
The probe works because of the unique fluorescence emission wavelength of DFO-NBD, but the 
low signal intensity generated by the probe naturally leads to elevated error due to low signal-to-
noise ratios in the measured assays. More fluorescently intense probes would also allow for lower 
concentrations to be used in the assays, allowing for conservation of material. Also, problems such 
as fluorescence increases or decreases when bound to a protein would become less impactful as 
the starting fluorescence intensity would be increased. 
The addition of whole-cell assays would provide a useful complement to the current work. 
One way to do this would be to grow S. aureus in iron deficient conditions similar to what is seen 
in the first chapter. Instead of the addition of a holo-siderophore as the iron source, holo-transferrin 
could be used in increasing concentrations to confirm the ability of S. aureus to utilize iron from 
holo-transferrin. Then increasing amounts of an apo-siderophore could be added at a set 
concentration of holo-transferrin to hopefully be able to observe increasing capability of S. aureus 
to utilize iron from holo-transferrin at increasing concentrations of apo-siderophore. This could be 
done in the reverse way in which increased concentrations of holo-transferrin could then be added 
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to a set concentration of apo-siderophore. Ultimately the results of this experiment would 
theoretically support the idea of apo-siderophore cofactors as important in the acquisition of iron 
from sources such as human holo-transferrin. Coupled to this idea would be testing S. aureus 
FhuD2-knockout strains and FhuD2-mutant strains by the same experimental setup. Presumably, 
S. aureus might be able to increasingly utilize holo-transferrin iron from its other siderophore 
uptake sources but increasing amounts of apo-siderophore specific to the FhuD2 system would 
ideally not have the same impact on growth recovery at a set concentration of holo-transferrin. The 
FhuD2 knockout strains separately isolated could be added back into the system at set 
concentrations of holo-transferrin and apo-siderophore, and growth recovery would ideally be 
observed. The S. aureus strains expressing mutated FhuD2 would provide a good comparison for 
the in vitro evaluation of FhuD2 mutants described in Chapter 3 to extend the findings to the more 
complex cellular context. 
The substrate scope of FhuD2 and YxeB could be expanded to additional biologically 
relevant iron sources. Heme is one example that has been tied to utilization by S. aureus, and 
acquisition of its iron has directly been tied to the native S. aureus siderophores.1 Lactoferrin and 
calprotectin are additional potential iron sources for invading pathogens since these are expressed 
as innate immune proteins that limit the concentration of free metal ions.9 Fluorescence quenching 
assays in the presence of these iron sources could be easily done using DFO-NBD and our 
established assay to determine the extent of SBPs to utilize different types of iron in an infection 
environment. 
Crystallographic work in the future through collaboration would be a useful way to provide 
insight on the shuttle mechanism. While two binding sites appear highly unlikely, the possibility 
does exist and capturing multiple siderophores bound to the protein would be invaluable in piecing 
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together specific mechanistic detail of the shuttle mechanism. The other aspect of the shuttle 
mechanism, the acquisition of iron from host defense proteins such as transferrin, would also 
greatly be aided by crystallographic insight. Due to transferrin’s size compared to FhuD2, it seems 
highly unlikely that transferrin would necessarily directly compete with siderophores for access to 
the binding pocket. Rather, protein-protein interaction inducing allosteric effects and placing the 
iron in holo-transferrin in close proximity to a bound apo-siderophore is needed. Observing a 
crystal structure of transferrin’s interaction with FhuD2 would provide possible confirmation of 
the legitimacy of this argument and reveal if this is an interaction specific to transferrin or general 
to many types of metalloproteins. 
One of the drawbacks of the current work is utilizing only the soluble SBP portion of the 
ABC transporter. Certain interactions with the SBP anchored to the membrane could end up 
affecting aspects of the shuttle or displacement mechanism in unknown ways. Nanodisc 
technology would allow for the observation of iron exchange or substrate displacement at the SBP 
in the context of the cellular membrane. Study of nanodisc or other lipid-based reconstitution of 
fully functional SBP and associated ATP-dependent permeases by native spray mass spectrometry 
or even crystallography would be especially insightful. 
The idea of refining a treatment for iron overload disease has additional room for 
exploration. The ability for a negatively charged siderophore such as danoxamine to be effective 
at treating iron overload while being much less easily utilized by a pathogen such as S. aureus 
could be explored through collaboration with labs equipped with mouse models of pathogen 
infection and iron overload disease. The iron affinity of danoxamine could be tuned to be higher 
in order to maintain similar treatment efficacy as desferrioxamine. Other factors important in the 
treatment of iron overload, such as ability to efficiently cycle out of the body, could be examined 
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in the case of danoxamine. Testing coadministration with some other popular iron overload 
treatments, such as deferasirox and deferiprone, would be another way to probe the potential of 
danoxamine as an iron overload treatment. The extent of mobilization intracellularly could be 
tested in a similar way as has been done with DFO with adamantane derivatives.2 
Multiple big picture questions about the nature of FhuD2 transport remain to be answered. 
Its role as a vaccine candidate cannot be ignored and points to its highly relevant role in S. aureus 
virulence.3 The precise nature of the interaction between FhuD2 and holo-transferrin could be 
hypothesized to be acting similar to macromolecular crowding, in which proteins interact not only 
with their specific substrate but also with bystander macromolecules, called molecular crowding 
agents. These nonspecific interactions are primarily facilitated via hydrophobic interactions of 
protein surfaces and can modulate protein activity and conformation.4 The stoichiometry of 
FhuD2’s shuttling function is unknown. The seeming lack of a second binding site on the protein 
points to the potential of a dimeric interaction with another SBP in order to shuttle iron from one 
siderophore to another. This dimeric interaction might not be necessary when acquiring iron from 
a source such as transferrin, but there is literature evidence that such dimeric interactions can 
occur.5 The possibility of direct iron binding to FhuD2 cannot be ignored. Direct metal binding is 
observed in a variety of SBPs, including CeuE.6,10 Perhaps part of the way it extracts iron from 
holo-transferrin is through direct coordination to the metal. Transport of iron from a holo-
siderophore already bound to the SBP could occur through binding to the iron and directly 
transporting it through the ABC transporter. There is literature evidence of direction iron chelation 
by SBPs and work here has shown direct fluorescence quenching of FhuD2 by FeCl3, so this 
remains a possibility to explore further.6  
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The development of a more complete picture of siderophore-mediated iron acquisition 
necessitates studying systems outside of the siderophore uptake portion. Siderophore efflux is one 
area that is would make a promising therapeutic target. The efflux transporter of staphyloferrin A, 
SfaA, has directly been linked to S. aureus proliferation in epithelial cells and abscesses, as mutants 
lacking SfaA exhibited noticeable growth defects.7 The specific mechanism of how efflux occurs, 
however, remains largely unknown. Iron release is another highly relevant portion of the 
siderophore iron acquisition pathway. While it typically occurs via a reductive mechanism, the 
mechanism of action of iron reduction, though linked to several proteins, has not been fully 
elucidated.8  
Additional SBPs could be explored to test the generality of the findings of enzymatic 
activity illustrated in this work, which are likely to be relevant for many SBPs in diverse pathogens 
beyond FhuD2 and YxeB in S. aureus and B. cereus, respectively. A multitude of different 
combinations of SBPs, iron sources, and apo-siderophore combinations could be analyzed for 
interplay of both the siderophore displacement and iron shuttle mechanisms. Different fluorescent 
probes may be necessary if DFO-NBD does not function as an adequate substrate for a SBP of 
interest, but there is vast room for expansion of these ideas into other systems. Knowledge about 
siderophore uptake in SBPs native to other types of bacteria could lay the groundwork for 
expanding the relevance of siderophore-mediated iron transport paradigms beyond S. aureus and 
provide and evolutionary context (at the residue level) for the emergence of catalysis (iron 








Figure 4.1. Newly presented siderophore-mediated uptake paradigm. Shown above is the 
previously understood system of siderophore function where the siderophore, after being effluxed 
from the cell, travels into the extracellular environment before eventually returning once bound to 
iron. In the revised paradigm, as shown below, the siderophore is effluxed from the cell but quickly 
binds a SBP anchored to the cell membrane. The apo-siderophore then serves as a cofactor to 
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A.1 Synthesis of the Ferrioxamine Library 
 
 
General materials and methods. The trihydroxamate siderophores 1–17 and the corresponding 
1:1 iron(III) complexes 1-Fe–17-Fe were synthesized as shown in Scheme 2.1.3 All reactions were 
carried out under a dry argon atmosphere unless otherwise stated. Dichloromethane (CH2Cl2) was 
distilled from calcium hydride. Tetrahydrofuran was distilled from Na/benzophenone. 
Dimethylformamide (DMF), diisopropylamine (iPr2EtN), and acetonitrile (CH3CN) were used 
from sealed anhydrous bottles purchased from Acros. Silica gel chromatography was performed 
using Sorbent Technologies silica gel 60 (32-63 m). 1H-NMR and 13C-NMR spectra were 
recorded on a 600 MHz Varian DirectDrive spectrometer and FIDs were processed using 
ACD/ChemSketch version 10.04. Chemical shifts () are given in parts per million (ppm) and are 
referenced to non-deuterated residual solvent. Coupling constants (J) are reported in hertz (Hz). 
High-resolution mass spectrometry measurements were obtained on a Bruker micrOTOF II using 
electrospray ionization (ESI) in positive ion mode. Sample was introduced via flow injection at 4 
L/min and mass spectra were recorded from 50–3000 m/z for two min. HPLC was performed on 
a Waters 1525 binary pump instrument with a Waters 2487 dual  absorbance detector set at 427 
nm and 254 nm. The operating software for the HPLC was Breeze version 3.30. The HPLC column 
was a YMC Pro C18 reverse phase (3.0 x 50 mm) fit with a guard column (2.0 x 10 mm) of the 
same composition. Mobile phases were 10 mM ammonium acetate in H2O (A) and 10 mM 
ammonium acetate in CH3CN (B). A gradient was formed from 5%–80% (B) over 10 min, then 
80%–95% (B) over 2 min, and then 95%–5% (B) over 3 min at a flow rate of 0.7 mL/min. Thin 
layer chromatography (TLC) was performed with aluminum-backed Merck RP-C18 F256 silica gel 
plates using a 254 nm lamp or aqueous FeCl3 stain for visualization. IR spectra were recorded on 
a Bruker Tensor series FT-IR spectrometer using a diamond ATR accessory or as a thin film on 
NaCl disks. Melting points were determined in capillary tubes using a Thomas Hoover melting 
point apparatus and are uncorrected. The purity of compounds tested in biological assays was 
















































































Step 1 Step 2




(only 20–31, 33–37 were 
carried on to next step)
Dan, DFOB, SDFOB, 1–16 Dan-Fe, FOB, SFOB, 1-Fe–16-Fe








Synthesis of siderophores. The N-Boc-tetra-O-benzylated precursor 18 was prepared according 
to well established a literature protocol.4 Treatment of 18 with TFA followed by an aqueous 
NaHCO3 quench gave amine 19 according to a literature protocol (Step 1).4 Amine 19 is the 
precursor for benzyl protected siderophores 20–38 (Fig. 2.15) and deprotected siderophores 1–17, 
Dan, and Dan-Cip. The synthesis and full characterization of siderophores 1, 2, 3, 5, 6, 7, 8, and 
17 and corresponding iron(III) complexes was reported previously.5 The synthesis and full 
characterization of Dan, Dan-Fe, and Dan-Cip was reported previously.4,6 DFOB was purchased 
from Sigma-Aldrich (St. Louis, MO). SDFOB was synthesized from DFOB as reported 
previously.7 General procedures for steps 3 and 4 are provided below along with detailed 
procedures for the synthesis of all new siderophores including benzyl protected precursors 22, 23, 
and 30–38, deprotected siderophores 4 and 9–16, and siderophore iron(III) complexes FOB, 
SFOB, and 4-Fe and 9-Fe–16-Fe. Siderophores were synthesized by Wencewicz at the University 
of Notre Dame and transferred to his laboratory at Washington University in St. Louis via a 
material transfer agreement. 
 
General procedure for step 3. Benzyl protected siderophore (22, 23, 30, 31, 33–37) was dissolved 
in MeOH (~0.01 M) in an HCl-washed flask with a magnetic stir bar. The flask was flushed with 
argon, charged with 10% Pd-C (~10% w/w), and flushed with H2 gas several times with 
intermediate vacuum evacuation. The mixture was left stirring under positive pressure from a H2 
balloon. Reaction progress was monitored by RP-C18 TLC (1.5:1 CH3CN:H2O; FeCl3 stain). Once 
complete as judged by TLC the flask was flushed with argon and the mixture was vacuum filtered 
through a pad of celite and concentrated under reduced pressure. Crude product was dissolved in 
a minimal amount of MeOH and precipitated by adding Et2O. The siderophore (4, 9–16) was 
isolated as a white solid after trituration with Et2O and drying under vacuum. 
 
General procedure for step 4. The siderophore (DFOB, SDFOB, 4, 9–16) was dissolved in 
MeOH (0.002 M) at 40 C (oil bath temp). Fe(acac)3 (1.1 equiv) was added to give a clear, orange 
solution that was stirred for 2 hr. The MeOH was removed under reduced pressure using rotary 
evaporation to give the siderophore-iron(III) complex as an orange film. The crude product was 
dissolved in a minimal amount of MeOH and precipitated by addition of Et2O, triturated with Et2O, 
and dried under vacuum to give the pure siderophore-iron(III) complex (FOB, SFOB, 4-Fe, 9-Fe–














FOB (mesylate salt). Desferrioxamine B mesylate (DFOB; 47.5 mg, 0.072 mmol) was complexed 
to Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex FOB 
in 98% yield as an orange powder (50.5 mg, 0.071 mmol). Mp 174–178 °C (dec.); HPLC retention 
time 2.06 min. 
 
 
SFOB. Succinyl-desferrioxamine B (SDFOB; 51 mg, 0.077 mmol) was complexed to Fe(III) 
according to the general procedure for step 4 to give siderophore-Fe(III) complex SFOB in 97% 




Benzyl protected siderophore 30. Hydroxylamine 19 (457.7 mg, 0.52 mmol), 2,2-
dimethylsuccinic anhydride (150.0 mg, 0.71 mmol), iPr2EtN (0.1 mL, 0.71 mmol), and catalytic 
DMAP (31 mg, 0.25 mmol) were dissolved in 8 mL of CH2Cl2, respectively. After 24 h, TLC (6% 
MeOH in CH2Cl2; FeCl3 stain) showed only trace remaining starting material (19). After 90 h, the 
reaction was quenched with 1 N HCl (10 mL). The aq. layer was extracted with CH2Cl2 (2 x 10 
mL) and the combined CH2Cl2 layers were washed with brine (10 mL), dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure. This gave 579.6 mg of a cloudy, 
viscous oil that was purified by silica gel column chromatography (0.75 x 3 in silica gel; 3% MeOH 
in CH2Cl2). Pure product (30) was obtained in 68% yield as a clear, colorless oil (355.1 mg, 0.35 
mmol). IR (thin film on NaCl plate) 3327, 2936, 2865, 1726, 1657, 1548, 1454, 1365, 1191 cm-1; 
1H-NMR (600 MHz, CDCl3) δ (ppm) 7.43–7.29 (m, 20 H), 6.81 (br s, 1 H), 6.58 (br s, 1 H), 4.85 
(s, 4 H), 4.80 (s, 2 H), 4.48 (s, 2 H), 3.71–3.59 (m, 6 H), 3.44 (t, J = 6.5 Hz, 2 H), 3.23–3.16 (m, 4 
H), 2.85 (t, J = 6.3 Hz, 2 H), 2.83–2.77 (m, 2 H), 2.69 (s, 2 H), 2.55 (t, J = 6.5 Hz, 2 H), 2.50 (t, J 
= 6.5 Hz, 2 H), 1.67–1.58 (m, 8 H), 1.52–1.42 (m, 4 H), 1.39–1.27 (m, 6 H), 1.25 (s, 6 H); 13C-
NMR (150 MHz, CDCl3) δ (ppm) 179.4, 174.5, 173.8, 173.2, 172.4, 172.3, 138.5, 134.3, 134.2, 
129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.6, 128.3, 127.5, 127.4, 76.3, 76.3, 76.0, 72.8, 
70.0, 45.4, 44.8, 43.9, 42.1, 39.9, 39.3, 39.2, 30.5, 30.4, 29.3, 28.6, 28.1, 28.0, 27.9, 26.6, 26.4, 



















































































































Siderophore 4. Benzyl protected siderophore 30 (51.8 mg, 0.051 mmol) was deprotected 
according to the general procedure for step 3 to give the siderophore 4 in 97% yield as a white 
solid (32.0 mg, 0.049 mmol). 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.62– 3.57 (m, 4 H), 3.55 (t, 
J = 6.5 Hz, 2 H), 3.21–3.13 (m, 6 H), 2.76 (t, J = 7.2 Hz, 2 H), 2.51 (s, 2 H), 2.48–2.43 (m, 6 H), 
1.70–1.60 (m, 4 H), 1.59–1.47 (m, 8 H), 1.44–1.29 (m, 6 H), 1.23 (s, 6 H); HRMS–ESI (m/z): 
[M+Na]+ calcd. For C29H53N5NaO11: 670.3634, found 670.3621. 
 
 
Siderophore-Fe(III) complex 4-Fe. Siderophore 4 (13.2 mg, 0.02 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 4-Fe in 
97% as an orange powder (13.9 mg, 0.02 mmol). Mp 130–140 °C (dec.); HRMS–ESI (m/z): 
[M+Na]+ calcd. for C29H50FeN5NaO11: 723.2749, found 723.2742; HPLC retention time 2.80 min. 
 
 
Benzyl protected siderophore 31. Hydroxylamine 19 (147.0 mg, 0.17 mmol), 3-
(methoxycarbonyl)-3-methylbutanoic acid8 (52.0 mg, 0.32 mmol), iPr2EtN (28.0 mg, 0.22 mmol), 
catalytic DMAP (5.1 mg, 0.04 mmol), and EDC-HCl (80.0 mg, 0.42 mmol) were dissolved in 10 
mL of CH2Cl2. After 19 h, TLC (6% MeOH in CH2Cl2; FeCl3 stain) showed no remaining starting 
material (19). The mixture was diluted with CH2Cl2 (10 mL), washed with 10% aq. citric acid (2 
x 10 mL), brine (10 mL), 10% aq. NaHCO3 (10 mL), and brine (10 mL), dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure to give 159.8 mg of a clear, colorless, 
viscous oil. The crude product was purified by silica gel column chromatography (1 x 3 in silica 
gel; 3%–6% MeOH in CH2Cl2). Pure product (31) was isolated in 73% yield as a clear, colorless, 
viscous oil (125.2 mg, 0.12 mmol). 1H-NMR (600 MHz, CDCl3) δ (ppm) 7.43–7.29 (m, 20 H), 
6.32 (br s, 2 H), 4.85 (s, 2 H), 4.85 (s, 2 H), 4.79 (s, 2 H), 4.48 (s, 2 H), 3.66 (s, 3 H), 3.65–3.56 
(m, 6 H), 3.44 (t, J = 6.5 Hz, 2 H), 3.22–3.17 (m, 4 H), 2.84–2.77 (m, 4 H), 2.67 (s, 2 H), 2.52–
2.45 (m, 4 H), 1.67–1.59 (m, 8 H), 1.53–1.45 (m, 4 H), 1.40–1.33 (m, 2 H), 1.32–1.25 (m, 4 H), 
1.22 (s, 6 H); 13C-NMR (150 MHz, CDCl3) δ (ppm) 177.9, 174.0, 173.8, 172.4, 172.1, 172.1, 
138.5, 134.5, 134.5, 134.3, 129.1, 129.1, 128.9, 128.9, 128.8, 128.7, 128.7, 128.6, 128.3, 127.5, 


















































































































29.1, 28.4, 28.1, 28.0, 26.7, 26.4, 26.4, 25.6, 25.3, 23.9, 23.6, 23.4; HRMS–ESI (m/z): [M+Na]+ 
calcd. for C58H79N5NaO11: 1044.5668, found 1044.5663. 
 
 
Siderophore 9. Benzyl protected siderophore 31 (64.4 mg, 0.063 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 9 in 93% yield as a white solid 
(38.7 mg, 0.058 mmol). Mp 138–140 °C; 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.65 (s, 3 H), 
3.59 (t, J = 6.5 Hz, 4 H), 3.55 (t, J = 6.9 Hz, 2 H), 3.55 (t, J = 6.5 Hz, 2 H), 3.16 (t, J = 6.9 Hz, 4 
H), 2.79 (s, 2 H), 2.76 (t, J = 7.2 Hz, 4 H), 2.45 (t, J = 7.2 Hz, 4 H), 1.67–1.59 (m, 6 H), 1.59–1.49 
(m, 6 H), 1.40–1.29 (m, 6 H), 1.24 (s, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 180.1, 175.1, 
175.0, 174.6, 174.5, 173.2, 62.9, 52.5, 49.0, 48.8, 43.5, 41.4, 40.4, 33.4, 31.6, 31.6, 30.1, 30.1, 
29.1, 29.1, 27.7, 27.5, 26.2, 25.1, 25.0, 24.1; HRMS–ESI (m/z): [M+H]+ calcd. for C30H56N5O11: 
662.3971, found 662.3971. 
 
 
Siderophore-Fe(III) complex 9-Fe. Siderophore 9 (11.5 mg, 0.017 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 9-Fe in 
86% yield as an orange powder (10.6 mg, 0.015 mmol). Mp 170–173 °C; HRMS–ESI (m/z): 
[M+H]+ calcd. for C30H53FeN5O11: 715.3086, found 715.3089; HPLC retention time 4.52 min. 
  
 
Benzyl protected siderophore 22. Benzyl protected siderophore 20 (298.2 mg, 0.30 mmol) was 
reacted with EDC-HCl (146.0mg, 0.76 mmol) and N-hydroxysuccinimide (NHS; 70.0 mg, 0.608 
mmol) in 5 mL of CH2Cl2 for 2 h. After an aqueous work-up, the NHS activated ester of 20 was 
isolated in 95% yield as a clear, viscous oil (312.4 mg, 0.29 mmol). The NHS activated ester of 20 
(52.1 mg, 0.048 mmol) was reacted with NH3 in MeOH (7N, 2.0 mL, 49 mmol) in CH2Cl2 (2 mL) 
for 2.5 h. All the volatiles were removed under reduced pressure giving 66.6 mg of a clear, tan oil. 
The crude product was purified by silica gel column chromatography (1 x 3 in silica gel; 3%–6% 
MeOH in CH2Cl2) to give the desired product (22) in 99% yield as a clear, colorless, viscous oil 
(47.5 mg, 0.049 mmol). 1H-NMR (600 MHz, CDCl3) δ (ppm) 7.41–7.29 (m, 20 H), 6.91 (br s, 1 
H), 6.50 (br s, 1 H), 6.36 (br s, 1 H), 6.06 (br s, 1 H), 4.85 (s, 2 H), 4.84 (s, 2 H), 4.84 (s, 2 H), 
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H), 2.83–2.77 (m, 4 H), 2.77–2.73 (m, 2 H), 2.57–2.50 (m, 4 H), 2.48 (t, J = 6.5 Hz, 2 H), 1.67–
1.58 (m, 8 H), 1.51–1.44 (m, 4 H), 1.39–1.23 (m, 6 H); 13C-NMR (150 MHz, CDCl3) δ (ppm) 
174.8, 174.2, 174.0, 173.8, 172.4, 172.3, 138.5, 134.4, 134.3, 129.2, 129.2, 129.1, 128.9, 128.8, 
128.7, 128.3, 127.6, 127.5, 76.3, 76.1, 72.8, 70.1, 63.7, 45.5, 44.8, 44.5, 39.4, 39.2, 30.6, 30.5, 
29.8, 29.6, 29.3, 28.6, 28.3, 28.1, 28.0, 27.3, 26.6, 26.4, 26.3, 23.6, 23.4; HRMS–ESI (m/z): 
[M+H]+ calcd. for C55H75N6O10: 979.5539, found 979.5531. 
 
 
Siderophore 10. Benzyl protected siderophore 22 (43.0 mg, 0.044 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 10 in 94% yield as an off-white 
solid (25.5 mg, 0.041 mmol). Mp 152–155 °C; 1H-NMR (600 MHz, DMSO-d6) δ (ppm) 9.61 (br 
s, N-OH, 3 H), 7.78 (t, J = 5.4 Hz, 2 H), 7.28 (br s, 1 H), 6.72 (br s, 1 H), 4.35 (t, J = 5.0 Hz, 1 H), 
3.45 (t, J = 7.0 Hz, 6 H), 3.39–3.34 (m, 2 H), 2.99 (q, J = 6.7 Hz, 4 H), 2.60–2.54 (m, 6 H), 2.26 
(t, J = 7.2 Hz, 6 H), 1.53–1.46 (m, 6 H), 1.44–1.34 (m, 6 H), 1.27–1.17 (m, 6 H); 13C-NMR (150 
MHz, DMSO-d6) δ (ppm) 173.6, 172.0, 171.9, 171.9, 171.3, 60.6, 47.2, 47.1, 38.4, 32.2, 29.9, 
29.5, 28.8, 27.6, 27.3, 26.2, 26.0, 23.5, 22.7; HRMS–ESI (m/z): [M+H]+ calcd. for C27H51N6O10: 
619.3661, found 619.3654. 
 
 
Siderophore-Fe(III) complex 10-Fe. Siderophore 10 (8.0 mg, 0.013 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 10-Fe in 
91% yield as an orange powder (7.9 mg, 0.012 mmol). Mp 138-144 °C (dec.); HRMS–ESI (m/z): 
[M+H]+ calcd. for C27H48FeN6O10: 672.2776, found 672.2763; HPLC retention time 2.53 min. 
 
 
Benzyl protected siderophore 23. The NHS activated ester of 20 (52.1 mg, 0.048 mmol) was 
reacted with Me2NH in MeOH (2.0 M, 2.0 mL, 4.0 mmol) in CH2Cl2 (2 mL) for 2.5 h. All the 
volatiles were removed under reduced pressure to give 61.7 mg of a clear, viscous oil. The crude 
product was purified by silica gel column chromatography (1 x 3 in silica gel; 3%–6% MeOH in 
CH2Cl2) to give pure product (23) in 99% yield as a clear, colorless, viscous oil (48.0 mg, 0.048 
mmol). 1H-NMR (600 MHz, CDCl3) δ (ppm) 7.42–7.30 (m, 20 H), 6.56 (br s, 1 H), 6.36 (br s, 1 
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2 H), 3.22–3.16 (m, 4 H), 3.03 (s, 3 H), 2.94 (s, 3 H), 2.83–2.75 (m, 6 H), 2.65–2.60 (m, 2 H), 2.48 
(t, J = 6.6 Hz, 4 H), 1.67–1.58 (m, 8 H), 1.52–1.45 (m, 4 H), 1.39–1.25 (m, 6 H); 13C-NMR (150 
MHz, CDCl3) δ (ppm) 174.0, 173.9, 173.8, 172.2, 172.1, 171.8, 138.5, 134.6, 134.3, 129.2, 129.1, 
129.1, 128.8, 128.7, 128.6, 128.6, 128.3, 127.5, 127.4, 76.3, 76.3, 76.2, 72.8, 70.1, 63.8, 45.5, 45.0, 
44.8, 39.3, 39.3, 37.1, 35.5, 30.7, 30.5, 29.6, 29.3, 28.9, 28.5, 28.1, 27.9, 27.5, 27.4, 26.7, 26.4, 




Siderophore 11. Benzyl protected siderophore 23 (44.5 mg, 0.044 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 11 in 99% yield as a white solid 
(28.0 mg, 0.043 mmol). Mp 143–145 °C; 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.60 (t, J = 6.9 
Hz, 6 H), 3.55 (t, J = 6.6 Hz, 2 H), 3.16 (t, J = 6.5 Hz, 4 H), 3.09 (s, 3 H), 2.93 (s, 3 H), 2.80–2.73 
(m, 6 H), 2.64 (t, J = 6.6 Hz, 2 H), 2.45 (t, J = 7.2 Hz, 4 H), 1.68–1.60 (m, 6 H), 1.59–1.48 (m, 6 
H), 1.40–1.29 (m, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 175.1, 175.1, 174.8, 174.6, 174.5, 
62.9, 40.4, 37.8, 36.0, 33.4, 31.6, 30.1, 30.1, 29.1, 28.9, 28.6, 27.7, 27.5, 25.1, 25.0, 24.1; HRMS–
ESI (m/z): [M+H]+ calcd. for C29H55N6O10: 647.3974, found 647.3984. 
 
 
Siderophore-Fe(III) complex 11-Fe. Siderophore 11 (10.0 mg, 0.0155 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 11-Fe in 
93% yield as an orange powder (10.0 mg, 0.014 mmol). Mp 114–119 °C (dec.); HRMS–ESI (m/z): 
[M+Na]+ calcd. for C29H51FeN6NaO10: 722.2908, found 722.2888; HPLC retention time 3.07 min. 
 
 
Benzyl protected siderophore 32. Hydroxylamine 19 (224.0 mg, 0.25 mmol), N-Boc-β-alanine 
(52.0 mg, 0.275 mmol), iPr2EtN (0.05 mL, 0.29 mmol), catalytic DMAP (4.5 mg, 0.037 mmol), 
and EDC-HCl (125.0 mg, 0.65 mmol) were dissolved in 8 mL of CH2Cl2. After 24 h, TLC (5% 
MeOH in CHCl3; FeCl3 stain) showed no remaining starting material (19). The mixture was diluted 
with CH2Cl2 (25 mL) and washed with 10% aq. citric acid (2 x 10 mL), brine (10 mL), 10% aq. 
NaHCO3 (2 x 10 mL), and brine (10 mL), dried over anhydrous MgSO4, filtered, and concentrated 
















































































































column chromatography (0.5 x 4 in silica gel; 3% MeOH in CHCl3). Pure product (32) was 
obtained in 96% yield as a waxy solid (253.6 mg, 0.24 mmol). Mp 68–70 °C; IR (thin film on 
NaCl plate) 3327, 2936, 2863, 1707, 1653, 1545, 1454, 1412, 1366, 1252, 1172 cm-1; 1H-NMR 
(600 MHz, CDCl3) δ (ppm) 7.40–7.22 (m, 20 H), 6.41 (br s, 1 H), 6.41 (br s, 1 H), 5.29 (br s, 1 
H), 4.84 (s, 4 H), 4.76 (br s, 2 H), 4.46 (s, 2 H), 3.67–3.57 (m, 6 H), 3.43 (t, J = 6.5 Hz, 2 H), 3.40–
3.35 (m, 2 H), 3.21–3.15 (m, 4 H), 2.83–2.75 (m, 4 H), 2.64–2.58 (m, 2 H), 2.51–2.44 (m, 4 H), 
1.66–1.57 (m, 8 H), 1.51–1.45 (m, 4 H), 1.42 (s, 9 H), 1.38–1.32 (m, 2 H), 1.32–1.23 (m, 4 H); 
13C-NMR (150 MHz, CDCl3) δ (ppm) 173.9, 173.7, 173.4, 172.0, 172.0, 155.8, 138.4, 134.2, 
134.0, 129.1, 129.1, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.2, 127.4, 127.3, 78.8, 76.2, 76.2, 
72.7, 69.9, 45.4, 45.0, 44.6, 39.2, 35.8, 32.5, 30.5, 30.4, 29.2, 28.9, 28.3, 28.0, 27.8, 26.5, 26.3, 




Benzyl protected siderophore 38. N-Boc-O-Benzyl protected siderophore 32 (121.0 mg, 0.115 
mmol) was dissolved in a 1:1 mixture of TFA:CH2Cl2 (4 mL). After 1.5 h, the TFA/CH2Cl2 were 
evaporated and the resulting oil was dissolved in CHCl3 (15 mL) and washed with satd. aq. 
NaHCO3 (20 mL). The layers were separated and the CHCl3 was dried over anhydrous MgSO4, 
filtered, and concentrated under reduced pressure to give the desired siderophore amine 38 in 82% 
yield as a clear, colorless, viscous oil (89.4 mg, 0.094 mmol). This material was used immediately 
in the next reactions without purification. 1H-NMR (500 MHz, CDCl3)  (ppm) 7.47–7.22 (m, 20 
H), 6.41 (br s, 2 H), 4.85 (s, 4 H), 4.81 (s, 2 H), 4.47 (s, 2 H), 3.71–3.56 (m, 6 H), 3.44 (t, J = 6.4 
Hz, 2 H), 3.24–3.15 (m, 4 H), 2.95 (t, J = 5.5 Hz, 2 H), 2.85–2.74 (m, 4 H), 2.59–2.52 (m, 2 H), 
2.52–2.41 (m, 4 H), 1.75 (br s, 2 H), 1.69–1.56 (m, 8 H), 1.54–1.44 (m, 4 H), 1.40–1.21 (m, 6 H); 
13C-NMR (125 MHz, CDCl3)  (ppm) 174.0, 173.8, 172.1, 172.1, 138.5, 134.3, 129.1, 129.1, 
128.9, 128.9, 128.8, 128.7, 128.7, 128.6, 128.3, 127.5, 127.4, 76.3, 76.3, 76.2, 72.8, 70.1, 45.5, 




Benzyl protected siderophore 33. Amine 38 (29.8 mg, 0.313 mmol) was reacted with 
methanesulfonyl chloride (5.5 mg, 0.048 mmol) in the presence of Et3N (0.013 mL, 0.093 mmol), 
and catalytic DMAP (1.0 mg, 0.008 mmol) in 3 mL of CH2Cl2. After 21 h, TLC (5% MeOH in 
CH2Cl2; FeCl3 stain) showed no remaining starting material (38). The reaction mixture was diluted 
with CH2Cl2 (10 mL), washed with 10% aq. citric acid (2 x 10 mL), brine (10 mL), 10% aq. 
NaHCO3 (10 mL), and brine (10 mL), dried over anhydrous MgSO4, filtered, and concentrated to 
















































































chromatography (0.5 x 4 in silica gel; 3%–5% MeOH in CH2Cl2) and pure product (33) was 
obtained in 85% yield as a clear, colorless, viscous oil (27.2 mg, 0.026 mmol). 1H-NMR (600 
MHz, CDCl3) δ (ppm) 7.43–7.24 (m, 20 H), 6.40 (br s, 1 H), 6.37 (br s, 1 H), 5.50 (t, J = 5.9 Hz, 
1 H), 4.85 (s, 6 H), 4.80 (s, 2 H), 4.48 (s, 2 H), 3.70–3.57 (m, 6 H), 3.44 (t, J = 6.6 Hz, 2 H), 3.38–
3.29 (m, 2 H), 3.23–3.15 (m, 4 H), 2.93 (s, 3 H), 2.85–2.74 (m, 4 H), 2.68 (t, J = 4.8 Hz, 2 H), 
2.55–2.43 (m, 4 H), 1.69–1.55 (m, 8 H), 1.54–1.44 (m, 4 H), 1.41–1.33 (m, 2 H), 1.33–1.21 (m, 4 
H); 13C-NMR (150 MHz, CDCl3) δ (ppm) 174.1, 173.8, 172.8, 172.2, 172.2, 138.5, 134.3, 134.0, 
129.3, 129.1, 129.1, 128.9, 128.9, 128.8, 128.7, 128.6, 128.3, 127.6, 127.5, 76.3, 76.3, 76.3, 72.8, 
70.1, 45.5, 44.9, 44.7, 40.0, 39.3, 38.7, 32.8, 30.7, 30.6, 29.7, 29.3, 29.0, 28.4, 28.1, 28.0, 26.7, 




Siderophore 12. Benzyl protected siderophore 33 (21.0 mg, 0.020 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 12 in 69% yield as an off-white 
solid (9.2 mg, 0.014 mmol). Mp 120–123 °C; 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.64–3.57 
(m, 6 H), 3.55 (t, J = 6.6 Hz, 2 H), 3.33 (d, J = 7.0 Hz, 2 H), 3.17 (t, J = 6.7 Hz, 2 H), 3.16 (t, J = 
6.7 Hz, 2 H), 2.95 (s, 3 H), 2.79–2.74 (m, 6 H), 2.45 (t, J = 7.2 Hz, 4 H), 1.68–1.60 (m, 6 H), 1.59–
1.49 (m, 6 H), 1.40–1.30 (m, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 175.1, 62.9, 49.7, 40.4, 
40.0, 33.4, 31.8, 31.7, 30.1, 30.1, 29.1, 27.7, 27.5, 25.1, 25.0, 24.1 (compound precipitated in NMR 




Siderophore-Fe(III) complex 12-Fe. Siderophore 12 (3.0 mg, 0.0045 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 12-Fe in 
97% yield as an orange powder (3.1 mg, 0.0043 mmol). Mp 147-152 °C (dec.); HRMS–ESI (m/z): 
[M+H]+ calcd. for C27H50FeN6O11S: 722.2602, found 722.2617; HPLC retention time 3.12 min. 
 
 
Benzyl protected siderophore 34. Amine 38 (29.8 mg, 0.31 mmol) was reacted with p-






































































































































and catalytic DMAP (1.0 mg, 0.008 mmol) in 3 mL of CH2Cl2. After 21 h, TLC (5% MeOH in 
CH2Cl2; FeCl3 stain) showed no remaining starting material (38). The reaction mixture was diluted 
with CH2Cl2 (10 mL), washed with 10% aq. citric acid (2 x 10 mL), brine (10 mL), 10% aq. 
NaHCO3 (10 mL), and brine (10 mL), dried over anhydrous MgSO4, filtered, and concentrated to 
give 32.0 mg of a clear, colorless, viscous oil. The crude product was purified by silica gel column 
chromatography (0.5 x 4 in silica gel; 3%–5% MeOH in CH2Cl2) and pure product (34) was 
obtained in 85% yield as a clear, colorless, viscous oil (29.3 mg, 0.0265 mmol). 1H-NMR (600 
MHz, CDCl3) δ (ppm) 7.74 (d, J = 8.2 Hz, 2 H), 7.41–7.30 (m, 20 H), 7.28 (d, J = 7.9 Hz, 2 H), 
6.37 (br s, 2 H), 5.71–5.66 (m, 1 H), 4.85 (s, 4 H), 4.74 (s, 2 H), 4.48 (s, 2 H), 3.68–3.58 (m, 6 H), 
3.44 (t, J = 6.5 Hz, 2 H), 3.23–3.17 (m, 4 H), 3.16–3.11 (m, 2 H), 2.84–2.76 (m, 4 H), 2.62 (t, J = 
5.3 Hz, 2 H), 2.52–2.44 (m, 4 H), 2.39 (s, 3 H), 1.68–1.56 (m, 8 H), 1.53–1.44 (m, 4 H), 1.40–1.32 
(m, 2 H), 1.32–1.22 (m, 4 H); 13C-NMR (150 MHz, CDCl3) δ (ppm) 174.0, 173.8, 172.8, 172.2, 
143.1, 138.5, 137.1, 134.3, 134.0, 129.6, 129.2, 129.1, 129.1, 129.1, 128.9, 128.8, 128.7, 128.7, 
128.6, 128.3, 127.5, 127.4, 126.9, 76.3, 76.3, 76.3, 72.8, 70.1, 45.5, 45.0, 44.7, 39.3, 38.7, 32.3, 
30.7, 30.6, 29.7, 29.3, 29.0, 28.4, 28.1, 28.0, 26.7, 26.4, 26.3, 23.8, 23.6, 23.4, 21.4; HRMS–ESI 
(m/z): [M+H]+ calcd. for C61H81N6O11S: 1105.5679, found 1105.5707. 
 
 
Siderophore 13. Benzyl protected siderophore 34 (22.0 mg, 0.02 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 13 in 89% yield as an off-white 
solid (13.2 mg, 0.018 mmol). Mp 116–118 °C; 1H-NMR (600 MHz, CD3OD) δ (ppm) 7.74 (d, J = 
8.5 Hz, 2 H), 7.38 (d, J = 8.2 Hz, 2 H), 3.59 (t, J = 7.0 Hz, 2 H), 3.59 (t, J = 6.9 Hz, 2 H), 3.56 (t, 
J = 6.9 Hz, 2 H), 3.54 (t, J = 6.6 Hz, 2 H), 3.16 (t, J = 6.9 Hz, 2 H), 3.16 (t, J = 6.9 Hz, 2 H), 3.09 
(t, J = 7.2 Hz, 2 H), 2.76 (t, J = 7.2 Hz, 4 H), 2.66 (t, J = 7.2 Hz, 2 H), 2.45 (t, J = 7.3 Hz, 2 H), 
2.45 (t, J = 7.0 Hz, 2 H), 2.43 (s, 3 H), 1.68–1.58 (m, 6 H), 1.58–1.48 (m, 6 H), 1.40–1.28 (m, 6 
H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 175.1, 174.3, 174.3, 172.7, 144.8, 138.9, 130.9, 128.2, 
62.9, 49.2, 49.1, 49.0, 40.4, 40.4, 40.2, 33.8, 33.4, 31.8, 31.7, 30.1, 29.1, 29.1, 27.7, 27.5, 27.5, 




Siderophore-Fe(III) complex 13-Fe. Siderophore 13 (6.0 mg, 0.008 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 13-Fe in 
97% yield as an orange powder (6.2 mg, 0.008 mmol). Mp 149–154 °C (dec.); HRMS–ESI (m/z): 




























































































Benzyl protected siderophore 37. Hydroxylamine 19 (224.0 mg, 0.25 mmol), N-Cbz-β-alanine 
(63.0 mg, 0.28 mmol), iPr2EtN (0.05 mL, 0.29 mmol), catalytic DMAP (4.5 mg, 0.037 mmol), and 
EDC-HCl (125.0 mg, 0.65 mmol) were dissolved in 8 mL of CH2Cl2. After 24 h, TLC (5% MeOH 
in CHCl3; FeCl3 stain) showed no remaining starting material (19). The mixture was diluted with 
CH2Cl2 (20 mL) and washed with 10% aq. citric acid (2 x 10 mL), brine (10 mL), 10% aq. NaHCO3 
(2 x 10 mL), and brine (10 mL), dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. This gave 301.8 mg of a cloudy oil that was purified by silica gel column 
chromatography (0.5 x 5 in silica gel; 3% MeOH in CHCl3). Pure product (37) was obtained in 
90% yield as a clear, colorless oil (242.7 mg, 0.22 mmol). 1HNMR (600 MHz, CDCl3) δ (ppm) 
7.41–7.21 (m, 25 H), 6.44 (br s, 1 H), 6.41 (br s, 1 H), 5.64 (br s, 1 H), 5.07 (s, 2 H), 4.84 (s, 4 H), 
4.75 (br s, 2 H), 4.47 (s, 2 H), 3.70–3.56 (m, 6 H), 3.47– 3.41 (m, 4 H), 3.21–3.14 (m, 4 H), 2.83–
2.76 (m, 4 H), 2.66–2.60 (m, 2 H), 2.51–2.43 (m, 4 H), 1.66–1.57 (m, 8 H), 1.51–1.43 (m, 4 H), 
1.39–1.32 (m, 2 H), 1.31–1.23 (m, 4 H); 13CNMR (150 MHz, CDCl3) δ (ppm) 173.9, 173.7, 173.2, 
172.0, 172.0, 156.2, 138.4, 136.5, 134.2, 134.0, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 
128.5, 128.3, 128.2, 127.8, 127.8, 127.4, 127.3, 76.2, 76.1, 72.7, 69.9, 66.3, 45.4, 44.9, 44.6, 39.1, 
36.3, 32.4, 30.5, 30.4, 29.2, 28.9, 28.3, 28.0, 27.8, 26.5, 26.3, 26.2, 23.8, 23.5, 23.3; HRMS–ESI 
(m/z): [M+Na]+ calcd. for C62H80N6NaO11: 1107.5777, found 1107.5760. 
 
 
Siderophore 16. N-Cbz-O-Benzyl protected siderophore 37 (37.0 mg, 0.034 mmol) was 
deprotected according to the general procedure for step 3 in the presence of methanesulfonic acid 
(4.0 mg, 0.042 mmol) to give the siderophore methanesulfonate salt of 16 in 90% yield as a light, 
pink solid (21.6 mg, 0.031 mmol). Mp 139–141 °C (dec.); 1H-NMR (600 MHz, CD3OD) δ (ppm) 
3.62 (t, J = 7.0 Hz, 2 H), 3.59 (t, J = 7.0 Hz, 4 H), 3.54 (t, J = 6.5 Hz, 2 H), 3.21–3.14 (m, 6 H), 
2.88 (t, J = 6.3 Hz, 2 H), 2.76 (t, J = 6.2 Hz, 4 H), 2.70 (s, 3 H), 2.45 (t, J = 7.0 Hz, 4 H), 1.69–
1.60 (m, 6 H), 1.59–1.49 (m, 6 H), 1.40–1.30 (m, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 
175.1, 174.6, 174.5, 172.2, 62.9, 52.3, 49.7, 49.0, 40.4, 40.4, 39.6, 36.8, 33.4, 31.6, 31.6, 30.5, 
30.2, 30.1, 29.2, 29.1, 29.0, 27.7, 27.5, 27.4, 25.0, 24.1; HRMS–ESI (m/z): [M+H]+ calcd. for 












































































Siderophore-Fe(III) complex 16-Fe. Siderophore 16 (11.0 mg, 0.016 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 16-Fe in 
91% yield as an orange powder (10.5 mg, 0.014 mmol). Mp 153–158 °C (dec.); HRMS–ESI (m/z): 
[M+H]+ calcd. for C26H48FeN6O9: 644.2827, found 642.2891; HPLC retention time 2.26 min.  
 
 
Benzyl protected siderophore 36. Hydroxylamine 19 (275.0 mg, 0.31 mmol), 4-((tert-
butyldimethylsilyl)oxy)butanoic acid (84.0 mg, 0.41 mmol), iPr2EtN (0.13 mL, 0.75 mmol), 
catalytic DMAP (11.0 mg, 0.09 mmol), and EDC-HCl (150.0 mg, 0.78 mmol) were dissolved in 
8 mL of CH2Cl2. After 27 h, TLC (9% MeOH in CH2Cl2; FeCl3 stain) showed no remaining 
starting material (19). The mixture was diluted with CH2Cl2 (30 mL) and washed with 10% aq. 
citric acid (30 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered, and concentrated 
under reduced pressure to give 417.8 mg of a waxy solid. The crude product was purified by silica 
gel column chromatography (1 x 5 in silica gel; 3%–5% MeOH in CH2Cl2) to give pure 36-O-TBS 
in 99% yield as a white, waxy solid (332.3 mg, 0.31 mmol). Mp 71–73 °C; 1H-NMR (600 MHz, 
CDCl3) δ (ppm) 7.41–7.30 (m, 20 H), 6.32 (br s, 1 H), 6.28 (br s, 1 H), 4.85 (s, 2 H), 4.85 (s, 2 H), 
4.81 (s, 2 H), 4.48 (s, 2 H), 3.68–3.59 (m, 8 H), 3.44 (t, J = 6.5 Hz, 2 H), 3.22–3.17 (m, 4 H), 2.84–
2.77 (m, 4 H), 2.55–2.44 (m, 6 H), 1.86–1.80 (m, 2 H), 1.67–1.59 (m, 8 H), 1.50 (dt, J = 14.9, 7.4 
Hz, 4 H), 1.36 (dt, J = 15.5, 7.7 Hz, 2 H), 1.33–1.25 (m, 4 H), 0.89 (s, 9 H), 0.04 (s, 6 H); 13C-
NMR (150 MHz, CDCl3) δ (ppm) 174.7, 174.0, 173.8, 172.1, 172.0, 138.5, 134.5, 134.3, 129.1, 
129.0, 128.9, 128.8, 128.8, 128.7, 128.6, 128.3, 127.5, 127.4, 76.3, 72.8, 70.1, 62.4, 45.5, 45.2, 
44.7, 39.4, 39.3, 39.3, 30.7, 30.6, 29.3, 29.1, 28.8, 28.4, 28.1, 28.0, 27.6, 26.7, 26.5, 26.4, 25.9, 
24.0, 23.6, 23.4, 18.3, -5.3; HRMS–ESI (m/z): [M+H]+ calcd. for C61H90N5O10Si: 1080.6451, 
found 1080.6466. Purified 36-O-TBS (224.0 mg, 0.21 mmol) was dissolved in 7 mL of anhydrous 
THF. TBAF (1 M in THF, 0.54 mL, 0.54 mmol) was added and the mixture was stirred at rt. After 
12 h, the THF was evaporated under reduced pressure and the crude material was purified by silica 
gel column chromatography (1 x 6 in silica gel; 3%–7% MeOH in CH2Cl2) to give the desired free 
alcohol product 36 in 28.4% yield (47.3% yield based on recovered 36-O-TBS) as a clear oil (56.8 
mg, 0.06 mmol). 1H-NMR (600 MHz, CDCl3) δ (ppm) 7.43–7.29 (m, 20 H), 6.42 (br s, 1 H), 6.18 
(br s, 1 H), 4.85–4.83 (m, 4 H), 4.83–4.80 (m, 2 H), 4.47 (s, 2 H), 3.71–3.56 (m, 8 H), 3.52–3.41 
(m, 4 H), 3.24–3.15 (m, 4 H), 2.84–2.75 (m, 2 H), 2.70–2.66 (m, 2 H), 2.59–2.53 (m, 2 H), 2.50–
2.43 (m, 2 H), 1.91–1.83 (m, 2 H), 1.69–1.46 (m, 12 H), 1.40–1.22 (m, 6 H); 13C-NMR (150 MHz, 
CDCl3) δ (ppm) 177.3, 175.2, 173.8, 172.2, 172.1, 138.5, 134.3, 129.2, 129.1, 129.0, 128.9, 128.8, 






























































































38.5, 30.8, 30.7, 30.5, 29.5, 29.3, 28.7, 28.1, 28.0, 27.3, 27.2, 26.7, 26.4, 26.3, 23.9, 23.7, 23.6, 
23.4; HRMS–ESI (m/z): [M+H]+ calcd. for C55H76N5O10: 966.5587, found 966.5578. 
 
 
Siderophore 15. Benzyl protected siderophore 36 (38.7 mg, 0.040 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 15 in 97% yield as a tan, 
hydroscopic solid (23.4 mg, 0.039 mmol). 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.64–3.52 (m, 8 
H), 3.47 (t, J = 7.2 Hz, 2 H), 3.17 (t, J = 6.7 Hz, 4 H), 2.79–2.73 (m, 2 H), 2.71–2.66 (m, 2 H), 
2.55 (t, J = 7.5 Hz, 2 H), 2.45 (t, J = 7.0 Hz, 4 H), 1.81 (quintet, J = 7.0 Hz, 2 H), 1.67–1.60 (m, 6 
H), 1.60–1.49 (m, 6 H), 1.40–1.26 (m, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 180.2, 175.7, 
175.1, 174.5, 62.9, 62.6, 48.9, 40.4, 39.5, 33.4, 31.7, 30.1, 30.0, 29.2, 29.1, 28.9, 28.4, 27.6, 27.5, 




Siderophore-Fe(III) complex 15-Fe. Siderophore 15 (8.5 mg, 0.014 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 15-Fe in 
99% yield as an orange powder (9.1 mg, 0.014 mmol). Mp 192–195 °C; HRMS–ESI (m/z): 
[M+H]+ calcd. for C27H49FeN5O10: 659.2823, found 659.2812; HPLC retention time 2.53 min. 
 
 
Benzyl protected siderophore 35. Hydroxylamine 19 (76.9 mg, 0.087 mmol), acetic anhydride 
(18 mg, 0.176 mmol), iPr2EtN (22.0 mg, 0.17 mmol), and catalytic DMAP (1.1 mg, 0.009 mmol) 
were dissolved in 6.0 mL of CH2Cl2. After 1 h, TLC (6% MeOH in CH2Cl2; FeCl3 stain) showed 
no remaining starting material (19). The mixture was diluted with CH2Cl2 (15 mL) and washed 
with 10% aq. citric acid (10 mL), brine (10 mL), 10% aq. NaHCO3 (10 mL), and brine (10 mL), 
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. This gave 68.5 
mg of a clear, colorless oil that was purified via silica gel column chromatography (0.75 x 4 in 
silica gel; 3%–6% MeOH in CH2Cl2). Pure product (35) was obtained in 54% yield as a clear, 
colorless oil (43 mg, 0.05 mmol). All characterization data matched that previously reported in the 
literature.9 1H-NMR (600 MHz, CDCl3) δ (ppm) 7.41–7.26 (m, 20 H), 6.34 (br s, 1 H), 6.32 (br s, 
1 H), 4.85 (s, 2 H), 4.84 (s, 2 H), 4.80 (s, 2 H), 4.48 (s, 2 H), 3.67–3.58 (m, 6 H), 3.44 (t, J = 6.46 









































































































Hz, 2 H), 3.22–3.18 (m, 4 H), 2.83–2.77 (m, 4 H), 2.50–2.47 (m, 4 H), 2.09 (s, 3 H), 1.67–1.59 
(m, 8 H), 1.52–1.48 (m, 4 H), 1.39–1.35 (m, 2 H), 1.33–1.26 (m, 4 H); 13CNMR (150 MHz, CDCl3) 
δ (ppm) 174.0, 173.8, 172.1, 172.1, 138.5, 134.3, 129.1, 129.1, 128.9, 128.9, 128.8, 128.7, 128.7, 
128.6, 128.3, 127.5, 127.4, 76.3, 76.3, 76.2, 72.8, 70.1, 45.5, 44.9, 44.7, 39.3, 39.3, 30.7, 30.6, 
29.3, 29.0, 28.4, 28.1, 28.0, 26.7, 26.5, 26.4, 23.9, 23.6, 23.4, 20.5; HRMS–ESI (m/z): [M+H]+ 
calcd. for C53H72N5O9: 922.5325, found 922.5362. 
 
 
Siderophore 14. Benzyl protected siderophore 35 (34.8 mg, 0.038 mmol) was deprotected 
according to the general procedure for step 3 to give siderophore 14 in 80% yield as a white solid 
(16.9 mg, 0.03 mmol). All characterization data matched that previously reported in the literature.9 
Mp 123–125 °C; 1H-NMR (600 MHz, CD3OD) δ (ppm) 3.60 (t, J = 6.9 Hz, 6 H), 3.19–3.13 (m, 6 
H), 2.77 (t, J = 7.2 Hz, 4 H), 2.48–2.43 (m, 4 H), 2.09 (s, 3 H), 1.67–1.60 (m, 4 H), 1.58–1.48 (m, 
8 H), 1.41–1.30 (m, 6 H); 13C-NMR (150 MHz, CD3OD) δ (ppm) 175.1, 174.7, 174.3, 174.2, 
173.2, 67.1, 62.9, 49.7, 49.2, 49.1, 48.9, 48.7, 40.5, 40.5, 40.4, 33.4, 32.5, 32.5, 32.5, 31.7, 31.7, 
30.3, 30.2, 30.1, 30.1, 29.1, 27.7, 27.5, 27.5, 25.4, 25.3, 25.1, 25.0, 24.4, 24.1, 22.7, 20.3, 15.6; 
HRMS–ESI (m/z): [M+Na]+ calcd. for C25H47N5NaO9: 584.3266, found 584.3291. 
 
 
Siderophore-Fe(III) complex 14-Fe. Siderophore 14 (10.0 mg, 0.018 mmol) was complexed to 
Fe(III) according to the general procedure for step 4 to give siderophore-Fe(III) complex 14-Fe in 
92% yield as an orange powder (10.0 mg, 0.016 mmol). Mp 164–167 °C; HRMS–ESI (m/z): 
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Appendix B: NMR, Raw Curves and Protein 
Sequences and Additional Compound Data 
























































































































































































ty Kd = 41 +/- 6 nM (FOB)
Kd = 61 +/- 9 nM (DFOB)
Kd = 25 +/- 3 nM (FOE)
Kd = 79 +/- 15 nM (holo-Tf)
Y191F



















Kd = 37 +/- 9 nM (FOB)
Kd = 67 +/- 11 nM (DFOB)
Kd = 19 +/- 2 nM (FOE)
Kd = 110 +/- 15 nM (holo-Tf)
Y193F



















Kd = 57 +/- 8 nM (FOB)
Kd = 97 +/- 51 nM (DFOB)
Kd = 88 +/- 33 nM (FOE)
Kd = 137 +/- 28 nM (holo-Tf)
W197A



















Kd = 30 +/- 9 nM (FOB)
Kd = 42 +/- 9 nM (DFOB)
Kd = 49 +/- 23 nM (FOE)
Kd = 109 +/- 28 nM (holo-Tf)
R199A



















Kd = 13 +/- 2 nM (FOB)
Kd = 51 +/- 10 nM (DFOB)
Kd = 16 +/- 3 nM (FOE)
Kd = 85 +/- 24 nM (holo-Tf)
Y278F


















Kd = 64 +/- 50 nM (FOB)
Kd = 61 +/- 24 nM (DFOB)
Kd = 28 +/- 9 nM (FOE)





















Fluorescence quenching of wild-type and mutant variants of N-His6-FhuD2 by siderophores and 
human holo-transferrin. Graphs depict intrinsic tryptophan fluorescence quenching (λexcitation = 
280 nm; λemission = 340 nm) of the SBPs and shows dose-dependent binding to siderophore 
ligands. Apparent Kd values were calculated using a single-binding mode model in GraphPad 



































































Fluorescence quenching (λexcitation = 475 nm; λemission = 560 nm) of DFO-NBD by holo-Tf 
with and without mutant FhuD2. 
 
 
Primary protein sequences of wild type SBPs and the truncated N-His6-tagged SBPs used in 
fluorescence quenching assays. 






























aPrelipoprotein signal sequence highlighted in magenta predicted using SignalIP-5.0.REF Soluble 
siderophore-binding domain highlighted in teal. bHexahistidine motif with thrombin cleavage 
site highlighted in yellow. Soluble siderophore-binding domain highlighted in teal. 
 
 
Supplementary Table 4. Codon optimized nucleotide sequences of truncated fhuD2 and yxeB. 




























































Determination of FO-NBD apparent log KFe using an EDTA competition study. The graph depicts 
relative percentage of FO-NBD remaining after treatment with 1.2 equivalents EDTA. FO-NBD 
concentration was determined by optical absorbance at 427 nm. The apparent ferric iron affinity 
(log KFe) was calculated from the decay plots as described previously for related siderophores. The 
shaded regions above and below the curve represent error bars for each data point along the 


























Fe(III) Exchange from FO-NBD to EDTA




SDS-PAGE analysis of N-His6-FhuD2 (~33.6 kDa) and N-His6-YxeB (~35.3 kDa) purified by Ni-
NTA affinity chromatography after heterologous expression in E. coli BL21(DE3) cells. Leftmost 




Fluorescence quenching of (a) wild-type N-His6-FhuD2 and (b) wild-type N-His6-YxeB by 
siderophores, human holo-transferrin, FeCl3, and ferric EDTA. Graphs depict intrinsic tryptophan 
fluorescence quenching (λexcitation = 280 nm; λemission = 340 nm) of the SBPs and shows dose-
dependent binding to siderophore ligands. Apparent Kd values were calculated using a single-
binding mode model in GraphPad Prism version 7.0b. N-His6-FhuD2 plots for DFO, Dan-Fe, Dan, 







Desferrioxamine B-2-(4-nitro-2,1,3-benzoxadiazol-7-yl) conjugate (DFO-NBD) is a “turn off” 
fluorescent probe triggered by chelation of iron(III). (a) Structure of DFO-NBD (fluorescence 
“on”) and FO-NBD (fluorescence quenched). (b) Fluorescence emission spectra (excitation = 475 
nm; emission = 540-600 nm) of 2 μM DFO-NBD with a wavelength of maximum fluorescence at 
~565 nm after 60 min incubation with variable concentrations of FeCl3 (0 – 8 M). (c) Graph of 
FeCl3 concentration versus relative fluorescence intensity of DFO-NBD at 2 M shows a 1:1 
stoichiometry for the formation of FO-NBD. Error bars in panels b and c represent standard 



































excitation = 475 nm
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